

(19)



(11)

EP 3 916 017 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
01.12.2021 Bulletin 2021/48

(51) Int Cl.:
C07K 16/28 (2006.01)

(21) Application number: **21166042.8**

(22) Date of filing: **19.12.2015**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **22.12.2014 US 201462095675 P**
17.09.2015 US 201562220199 P
04.11.2015 US 201562251082 P
30.11.2015 US 201562261118 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
15821000.5 / 3 237 446

(71) Applicant: **PD-1 Acquisition Group, LLC**
New York, NY 10168 (US)

(72) Inventors:
• **AMIRINA, Najmia**
Somerville, MA 02144 (US)
• **CHAMARTHI, Hareesh**
Cambridge, MA 02140 (US)
• **CHIU, Maria, Isabel**
Newton Centre, MA 02459 (US)
• **DOTY, Daniel**
Arlington, MA 02474 (US)
• **FENG, Bin**
Newton, MA 02465 (US)
• **JONCA, Aleksander**
Boston, MA 02128 (US)

- **MCQUADE, Thomas**
Somerville, MA 02144-2711 (US)
- **NGUYEN, Anhco**
Needham, MA 02492 (US)
- **RANGANATH, Sheila**
Arlington, MA 02474 (US)
- **SCHEUPLEIN, Hans Albert Felix**
Arlington, MA 02465 (US)
- **SPAULDING, Vikki, A.**
Acton, MA 01720 (US)
- **WANG, Lei**
Braintree, MA 02184 (US)
- **WATKINS-YOON, Jennifer**
Brighton, MA 02135 (US)
- **VADDE, Sri Sahitya**
Ashland, MA 01721 (US)

(74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)

Remarks:

- This application was filed on 30-03-2021 as a divisional application to the application mentioned under INID code 62.
- Claims filed after the date of filing of the application / after the date of receipt of the divisional application (Rule 68(4) EPC).

(54) **ANTI-PD-1 ANTIBODIES**

(57) Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.

EP 3 916 017 A1

Description

RELATED APPLICATIONS

5 **[0001]** This application claims the benefit of U.S. Provisional Application No. 62/095,675, filed on December 22, 2014, U.S. Provisional Application No. 62/220,199, filed on September 17, 2015, U.S. Provisional Application No. 62/251,082, filed on November 4, 2015, and U.S. Provisional Application No. 62/261,118, filed on November 30, 2015. The entire teachings of the above applications are incorporated herein by reference.

10 INCORPORATION BY REFERENCE OF MATERIAL IN ASCII TEXT FILE

[0002] This application incorporates by reference the Sequence Listing contained in the following ASCII text file being submitted concurrently herewith:

15 a) File name: 50911000005SequenceListing.txt; created December 17, 2015, 73 KB in size.

BACKGROUND OF THE INVENTION

20 **[0003]** Modulation of the mammalian adaptive immune response (immunomodulation) is a useful therapeutic approach for various diseases and disorders. One way to achieve such immunomodulation is to intervene at one or more immune checkpoints, e.g., the Programmed Death-1 (PD-1) checkpoint. The natural function of immune checkpoints is to suppress the immune response, as necessary, to prevent immune damage to normal tissue. Depending on the disease or disorder, it may be desirable to upregulate or downregulate the immune response. Tumor cells that display non-self-antigens can evade immune attack by secreting cytokines or ligands that activate immune checkpoints. Therefore, in cancer therapy, 25 it is generally desirable to upregulate the immune response against tumor cells. In contrast, in treatment of autoimmune diseases, it is generally desirable to downregulate the immune response in certain tissues.

[0004] "Programmed Death-1" (PD-1) protein (also known as Programmed Cell Death Protein 1 and CD279) is a type I transmembrane receptor that is part of the extended CD28/CTLA4 family of T cell regulators. Ligands for PD-1 include PD-1 Ligand 1 (PD-L1, also known as B7-H1), and PD-1 Ligand 2 (PD-L2, also known as B7-DC).

30 **[0005]** PD-1 is expressed on various cell types, including T cells, B cells, and macrophages. Experimental data implicate the interactions of PD-1 with its ligands in downregulation of central and peripheral immune responses. Proliferation of T cells is inhibited in the presence of PD-L1. Mice with a disrupted PD-1 gene exhibit an autoimmune phenotype. PD-1 deficiency in the C57BL/6 mice results in chronic progressive lupus-like glomerulonephritis and arthritis (Nishimura et al., J. Exp. Med. 101(5):891-98, 2000).

35 **[0006]** Compounds that modulate PD-1 activity have potential as therapeutic agents for the treatment of various diseases and disorders, including cancer, inflammation, and autoimmune diseases. There is a significant unmet need for immunomodulatory compounds, e.g., antibodies, including PD-1 agonists and PD-1 antagonists.

SUMMARY OF THE INVENTION

40 **[0007]** The present invention provides antibodies that bind to PD-1. In some embodiments, the invention provides an isolated antibody that binds to PD-1, comprising a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 1-26 and/or a light chain variable region (LCVR) selected from the group consisting of SEQ ID NOs: 27-53. The invention also provides an isolated antibody that binds to PD-1 and competitively inhibits the binding of any 45 of the antibodies disclosed herein to PD-1.

[0008] In some embodiments, the invention also provides an isolated antibody that binds to PD-1, comprising a HCVR selected from the group consisting of SEQ ID NOs: 85-90 and/or a LCVR selected from the group consisting of SEQ ID NOs: 91-96.

50 **[0009]** The invention further provides an isolated antibody that binds to PD-1, wherein the antibody binds to a sequence in PD-1 selected from the group consisting of SEQ ID NOs: 54-84.

[0010] The antibodies can be used as therapeutic agents. For use as therapeutic agents, the antibodies disclosed herein can be engineered, e.g., humanized, to reduce or eliminate serum sickness or an undesired immune response when administered to a human patient. Also disclosed are methods of treating diseases and disorders in which the PD-1 signaling pathway plays a significant role ("PD-1-mediated diseases and disorders").

55 **[0011]** The present invention includes the surprising discovery that contacting human T cells with an effective amount of an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of T cells, and an effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cells increases T cell effector function to a greater extent than an equivalent

amount of either anti-PD-1 antibody alone. In some embodiments, the combination yields an additive effect on T cell effector function. In some embodiments, the combination yields a synergistic effect on T cell effector function.

[0012] Accordingly, the present invention provides a method for increasing T cell effector function, comprising contacting a T cell with a combination of: (a) an effective amount of an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell; and (b) an effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell.

[0013] In some embodiments, the present invention also provides a method for increasing T cell effector function, comprising contacting a T cell with an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell.

[0014] Additionally, the present invention provides a method for increasing lymphocyte secretion of a cytokine selected from the group consisting of IL-6, IL-12, IL-18, TNF- α , IL-1 β and GM-CSF in a human patient in need of increased T cell effector function, comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell.

[0015] The present invention provides a method of treating cancer in a mammal, comprising contacting a T cell in a mammal in need thereof with a combination of: (a) an effective amount of an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell; and (b) an effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell.

[0016] The present invention provides a method of producing anti-PD-1 antibodies comprising a HCVR, a LCVR, or a combination thereof. Accordingly, also provided herein is an isolated nucleic acid comprising a nucleotide sequence encoding the HCVR and/or LCVR of the present disclosure, as well as a host cell comprising an isolated nucleic acid of the invention.

[0017] The antibodies of the present invention can also be used in diagnostic testing. For example, the invention provides a method of diagnosing a PD-1-mediated disease or disorder, e.g., adaptive immune resistance, in a patient who has cancer.

[0018] These and other aspects and advantages of the invention will become apparent upon consideration of the following figures, detailed description and claims. As used herein, "including" means without limitation, and the examples cited are non-limiting.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The invention can be more completely understood with reference to the following drawings.

[0020] FIG. 1 is an alignment of the sequences of 26 heavy chain variable regions (HCVR) from antibodies that bind to human PD-1. The lower segment of the sequences is a continuation of the upper segment. Framework regions FR1 through FR4 are indicated. Complementarity determining regions CDR1 through CDR3 are also shown.

[0021] FIG. 2 is an alignment of the sequences of 27 light chain variable regions (LCVR) from antibodies that bind to human PD-1. The lower segment of the sequences is a continuation of the upper segment. Framework regions FR1 through FR4 are indicated. Complementarity determining regions CDR1 through CDR3 are also shown.

[0022] FIG. 3 is a bar graph summarizing data on binding of 32 mouse anti-human-PD-1 antibodies to PD-1-HIS. The specific HCVR and LCVR pairings for the 32 antibodies are indicated in the boxed text. Binding was evaluated by ELISA. Data represent average of two experiments.

[0023] FIG. 4 is a bar graph summarizing results from assays to measure the effectiveness of anti-PD-1 antibodies in relieving PD-L1 dependent inhibition of activation of human peripheral blood mononuclear cells (PBMCs). Treatments of cells were carried out in 96-well plates for 3-5 days. All treatments included plate-bound CD3 and soluble CD28 in PBS. Cells were treated additionally with nothing (positive control); with PD-L1 alone; or with PD-L1 plus an anti-PD-L1 antibody (EH12.2H7, pembrolizumab, 246A10 or 244C8). At the end of the treatment period, cells were transferred to a microwell array for IFN γ determination at the level of individual cells, with sample cell populations in the range of approximately 50-100 cells.

[0024] FIG. 5 is a bar graph summarizing the results of differential T cell activation in response to PD-1 blockade. These results indicate that antibodies 388D4, 413E1, 246A10 and 244C8 elicited similar secretion levels or enhanced secretion levels of IFN γ and TNF α as compared to antibody EH12.2H7 or pembrolizumab, under conditions of suboptimal activation (achieved by the treatment with anti-CD3 and anti-CD28), which may mimic activation conditions that occur *in vivo*.

[0025] FIG. 6 is a bar graph summarizing the results of antigen recall assays using cytomegalovirus in human PBMC. These results indicate that anti-PD-1 antibodies 246A10, 244C8, 413D2, 388D4, and 413E1 induce increased levels of IFN γ compared to antibody isotype controls.

[0026] FIGS. 7A and 7B summarize the results of mixed lymphocyte reaction assays using anti-PD-1 antibodies and human PBMCs. Humanized versions of clone 388D4 ("D4-HC3+LC1"; "D4-HC1+LC3"; and "D4-HC3+LC3") appear to induce cytokine release (FIG. 7A) and CD25 upregulation (FIG. 7B) similar to nivolumab. Humanized versions of clone

244C8 ("C8-HC1+LC1"; "C8-HC1+LC3"; and "C8-HC2+LC1") appear to induce increased levels of cytokine release (IFN γ) compared with 388D4 or nivolumab (FIG. 7A). T cells incubated with 244C8 also appear to exhibit a higher degree of activation, as inferred from CD25 expression (FIG. 7B).

[0027] FIG. 8 indicates regions within the PD-1 amino acid sequence (SEQ ID NO:97) bound by certain antibodies of the present invention (246A10, 244C8, 388D4, 413D2, and 413E1), as determined by peptide mapping. The PD-1 amino acid sequences corresponding to the sequences of inhibitory peptides are underlined.

[0028] FIGS. 9A-9D show selectivity of anti-PD-1 antibodies for the PD-1 extracellular domain over other immunomodulatory cell surface proteins such as ICOS (inducible T-cell costimulator) (FIG. 9A), CD28 (FIG. 9C), or CTLA4 (FIG. 9D). Binding of anti-PD-1 antibodies to PD-1 is shown in FIG. 9B (EH12.2H7 is an anti-PD-1 antibody commercially available as a laboratory reagent). Anti-PD-1 antibodies 388D4 (100388_D4VH3_100389_D4VK5 in Table 3), 413E1 (100413_E1VH9_100414_E1VK5 in Table 3), 244C8, and 246A10 were tested.

[0029] FIGS. 10A and 10B are amino acid sequence alignments of humanized and mouse antibody sequences. FIG. 10A shows alignments for 100388_D4_VH3 (mouse) with humanized heavy chain variable regions (100388_D4_HC1; 100388_D4_HC2; and 100388_D4_HC3) and 100389_D4_VK5 (mouse) with humanized light chain variable regions (100389_D4_LC1; 100389_D4_LC2; and 100389_D4_LC3). FIG. 10B shows alignments for 100244_C8_VH3 (mouse) with humanized heavy chain variable regions (100244_C8_HC1; 100244_C8_HC2; and 100244_C8_HC3) and 100245_C8_VK5 (mouse) with humanized light chain variable regions (100245_C8_LC1; 100245_C8_LC2; and 100245_C8_LC3).

[0030] FIGS. 11A-11D are flow cytometry histogram plots showing that antibody 388D4 blocks binding of soluble PD-L1 to HEK293 cells expressing PD-1, while antibody 244C8 does not. HEK293 cells expressing PD-1 were incubated with 10 μ g/ml of an isotype antibody (negative control), commercially available antibody EH12.2H7 (positive control) antibody 388D4, or antibody 244C8. Cells were washed and stained with soluble PD-L1-Ig protein fluorescently labeled with Alexa-488. Cells were washed again, and PD-L1 binding (by displacing previously bound antibody) was assessed by conventional fluorescence activated cell sorting (FACS) analysis. FIG. 11A shows data from FACS analysis of anti-PD-1 antibody EH12.2H7 (positive control); FIG. 11B shows data from FACS analysis of anti-PD-1 antibody mIgG1K (negative control); FIG. 11C shows data from FACS analysis of anti-PD-1 antibody 388D4; FIG. 11D shows data from FACS analysis of anti-PD-1 antibody 244C8.

[0031] FIG. 12 is a histogram showing restoration of T cell function by PD-1 blockade with nivolumab or different humanized forms of antibodies 388D4 and 244C8, *i.e.*, 388D4-2, 388D4-3, 244C8-1, 244C8-2, and 244C8-3. A population of 3×10^5 dissociated and suspended human cells from a non-small cell lung cancer (NSCLC) biopsy, which included 17% lymphocytes (activated as described above) was incubated for 24 hours with anti-PD-1 antibodies at a concentration of 20 μ g/mL. IFN γ was measured by ELISA, and the data are expressed in terms of fold-activation relative to treatment with the isotype control antibody. Each of the anti-PD-1 antibodies restored T cell function, increasing IFN γ secretion approximately 7-fold to 7.5 fold, relative to the isotype control.

[0032] FIG. 13 is a histogram summarizing results from an experiment to measure the increase in T cell effector function, as indicated by IFN γ secretion, in response to treatment with antibody 244C8-2 alone versus treatment with 244C8-2 plus 388D4-2, with results normalized relative to the response to treatment with nivolumab. A population of 3×10^5 cells, which included 7.5% lymphocytes sub-optimally activated as described above, was incubated for 24 hours with anti-PD-1 antibodies at a total antibody concentration of 20 μ g/mL. As shown in FIG. 13, treatment with 244C8-2 alone increased IFN γ 1.77-fold (\pm 0.19 sd), while treatment with 244C8-2 in combination with 388D4-2 increased IFN γ secretion 2.11-fold (\pm 0.21 sd).

[0033] FIG. 14 is a histogram summarizing results from an experiment showing that treatment with the combination of nivolumab and antibody 244C8-2 resulted in greater restoration of T cell effector function than treatment with nivolumab alone, antibody 244C8-2 alone, or antibody 388D4-2 alone. In each treatment, a population of 3×10^5 cells, which included 9% lymphocytes (sub-optimally activated as described above) was incubated for 24 hours with anti-PD-1 antibodies at a total concentration of 20 μ g/mL. Following PD-1 blockade, cells and supernatants were collected for ELISA measurement of IFN γ . Data are expressed in terms of fold-induction of IFN γ secretion, relative to treatment with the isotype control antibody.

[0034] FIGS. 15A-15F are histograms summarizing the results of a mixed lymphocyte reaction (MLR) assay performed on human PBMCs treated with anti-PD-1 antibodies. The MLR assay was performed using commercially available monocyte-derived dendritic cells as stimulator cells and purified CD4 $^+$ T lymphocytes as responder cells from a different healthy blood donor. Supernatants were collected 2.5 days after beginning the assay. Treatment with antibody 244C8-1 (100244_C8_HC1 + 100245_C8_LC1) resulted in increased secretion of cytokines IL-6, IL-12, IL-18, TNF- α , GM-CSF, and IL-1 β , in comparison with antibody 388D4-2 (100388_D4_HC3 + 100389_D4_LC3) or an IgG4 isotype control. (FIG. 15A, IL-6; FIG. 15B, IL-12; FIG. 15C, IL-18; FIG. 15D TNF- α ; FIG. 15E, IL-1 β ; FIG. 15F, GM-CSF)

[0035] FIGS. 16A-16F are histograms summarizing the results of an experiment showing alteration of tumor infiltrating lymphocyte (TIL) function by PD-1 blockade with anti-PD-1 antibodies 388D4-2 and 244C8-2. A population of 3×10^5 dissociated and suspended human cells from a non-small cell lung cancer (NSCLC) biopsy, which included 7% stimulated,

tumor-infiltrating lymphocytes was incubated for 24 hours with anti-CD3 and anti-CD28 antibodies along with an anti-PD-1 antibody or IgG4 isotype control at a concentration of 10 μ g/mL. Treatment with antibody 244C8-2 (100244_C8_HC1 + 100245_C8_LC3) resulted in increased secretion of cytokines IL-6, IL-12, IL-18, TNF- α , GM-CSF, and IL-1 β , in comparison with antibody 388D4-2 (100388_D4_HC3 + 100389_D4_LC3) or the IgG4 isotype control. (FIG. 16A, IL-6; FIG. 16B, IL-12; FIG. 16C, IL-18; FIG. 16D TNF- α ; FIG. 16E, IL-1 β ; FIG. 16F, GM-CSF).

[0036] FIGS. 17A-17C show the results from an *in vivo* efficacy experiment involving patient-derived xenograft (PDX) lung tumor growth in humanized mice treated with vehicle control, antibody 388D4-3, antibody 244C8-2, pembrolizumab, or a combination of antibody 244C8-2 and pembrolizumab. Animals received a total of six intra-peritoneal doses of antibody at five-day intervals (Q5D x 6) 5 mg/kg. In the treatment groups that received 388D4-3, 244C8-2 or pembrolizumab, the first dose of the antibody was given as a 10 mg/kg dose, followed by the additional doses at the 5 mg/kg dose. The combination treatment group received a dose of each 5 mg/kg of pembrolizumab and 5 mg/kg of 244C8-2 at each dosing time point. Tumor volumes were measured twice weekly (Day 3, 6, 10, 13, 17, 20, 24 and 28) using a digital caliper to determine length and width of the tumors. All animals were sacrificed at day 28 after dosing initiation. Error bars represent the 95% confidence interval (n=10). All treatment groups showed significant tumor growth inhibition compared to the vehicle control group. As shown in FIG. 17A, no significant difference in tumor growth inhibition was observed among treatment with antibody 388D4-3, antibody 244C8-2, pembrolizumab, or the combination of antibody 244C8-2 with pembrolizumab. FIG. 17B is a boxplot of tumor volumes for each treatment arm at day 28 (end of study) of the experiment described in FIG. 17A. The tumor volume for each treatment group was significantly smaller than that of the vehicle group. Student T-test p values between each treatment group and vehicle group were: 0.00167 (pembrolizumab), 0.00105 (388D4-3), 0.00277 (244C8-2), and 0.00275 (pembrolizumab+244C8), respectively. FIG. 17C is a histogram showing percentage tumor volume of each treatment group relative to vehicle on day 28 of the experiment described in FIGS. 17A and 17B. The calculated percent tumor growth inhibition (%TGI) for each treatment is shown above each bar.

DETAILED DESCRIPTION OF THE INVENTION

[0037] The anti-PD-1 antibodies disclosed herein are based on the antigen binding sites of certain monoclonal antibodies selected on the basis of binding to human Programmed Death-1 (PD-1) protein (UniProt#Q15116). The antibodies contain immunoglobulin variable region CDR sequences that define binding sites for human PD-1.

[0038] By virtue of the PD-1 signal blocking or PD-1 neutralizing activity of certain of these antibodies, they are useful for treating various types of cancer, including inhibiting tumor growth. In some embodiments (e.g., when used as therapeutic agents), the antibodies can be engineered to minimize or eliminate an immune response when administered to a human patient. Various features and aspects of the invention are discussed in more detail below.

[0039] As used herein, "isolated antibody" means an antibody that is substantially free of its natural environment. For instance, an isolated antibody or nucleic acid is substantially free of cellular material and other proteins from the cell or tissue source from which it is derived.

[0040] As used herein, unless otherwise indicated, "antibody" means an intact antibody or antigen-binding fragment of an antibody, including an intact antibody or antigen-binding fragment that has been modified or engineered, or that is a human antibody. Examples of antibodies that have been modified or engineered are chimeric antibodies, humanized antibodies, multiparatopic antibodies (e.g., biparatopic antibodies), and multispecific antibodies (e.g., bispecific antibodies). Examples of antigen-binding fragments include Fab, Fab', F(ab')₂, Fv, single chain antibodies (e.g., scFv), minibodies and diabodies.

[0041] The antibodies disclosed herein comprise: (a) an immunoglobulin heavy chain variable region comprising the structure CDR_{H1}-CDR_{H2}-CDR_{H3}, and (b) an immunoglobulin light chain variable region comprising the structure CDR_{L1}-CDR_{L2}-CDR_{L3}, wherein the heavy chain variable region and the light chain variable region together define a single binding site for binding human PD-1 protein.

[0042] In some embodiments, the isolated antibody that binds to PD-1 comprises a heavy chain variable region (HCVR) having complementarity determining regions (CDRs) selected from the group consisting of: CDRs 1-3 of SEQ ID NO: 1; CDRs 1-3 of SEQ ID NO: 2; CDRs 1-3 of SEQ ID NO: 3; CDRs 1-3 of SEQ ID NO: 4; CDRs 1-3 of SEQ ID NO: 5; CDRs 1-3 of SEQ ID NO: 6; CDRs 1-3 of SEQ ID NO: 7; CDRs 1-3 of SEQ ID NO: 8; CDRs 1-3 of SEQ ID NO: 9; CDRs 1-3 of SEQ ID NO: 10; CDRs 1-3 of SEQ ID NO: 11; CDRs 1-3 of SEQ ID NO: 12; CDRs 1-3 of SEQ ID NO: 13; CDRs 1-3 of SEQ ID NO: 14; CDRs 1-3 of SEQ ID NO: 15; CDRs 1-3 of SEQ ID NO: 16; CDRs 1-3 of SEQ ID NO: 17; CDRs 1-3 of SEQ ID NO: 18; CDRs 1-3 of SEQ ID NO: 19; CDRs 1-3 of SEQ ID NO: 20; CDRs 1-3 of SEQ ID NO: 21; CDRs 1-3 of SEQ ID NO: 22; CDRs 1-3 of SEQ ID NO: 23; CDRs 1-3 of SEQ ID NO: 24; CDRs 1-3 of SEQ ID NO: 25; and CDRs 1-3 of SEQ ID NO: 26.

[0043] In some embodiments, the isolated antibody that binds to PD-1 comprises a HCVR selected from the group consisting of SEQ ID NOs: 1-26.

[0044] In some embodiments, the isolated antibody that binds to PD-1 comprises a light chain variable region (LCVR)

having CDRs selected from the group consisting of: CDRs 1-3 of SEQ ID NO: 27; CDRs 1-3 of SEQ ID NO: 28; CDRs 1-3 of SEQ ID NO: 29; CDRs 1-3 of SEQ ID NO: 30; CDRs 1-3 of SEQ ID NO: 31; CDRs 1-3 of SEQ ID NO: 32; CDRs 1-3 of SEQ ID NO: 33; CDRs 1-3 of SEQ ID NO: 34; CDRs 1-3 of SEQ ID NO: 35; CDRs 1-3 of SEQ ID NO: 36; CDRs 1-3 of SEQ ID NO: 37; CDRs 1-3 of SEQ ID NO: 38; CDRs 1-3 of SEQ ID NO: 39; CDRs 1-3 of SEQ ID NO: 40; CDRs 1-3 of SEQ ID NO: 41; CDRs 1-3 of SEQ ID NO: 42; CDRs 1-3 of SEQ ID NO: 43; CDRs 1-3 of SEQ ID NO: 44; CDRs 1-3 of SEQ ID NO: 45; CDRs 1-3 of SEQ ID NO: 46; CDRs 1-3 of SEQ ID NO: 47; CDRs 1-3 of SEQ ID NO: 48; CDRs 1-3 of SEQ ID NO: 49; CDRs 1-3 of SEQ ID NO: 50; CDRs 1-3 of SEQ ID NO: 51; CDRs 1-3 of SEQ ID NO: 52; and CDRs 1-3 of SEQ ID NO: 53.

[0045] In some embodiments, the isolated antibody that binds to PD-1 comprises a LCVR selected from the group consisting of SEQ ID NOs: 27-53.

[0046] In some embodiments, the isolated antibody that binds to PD-1 comprises a HCVR selected from the group consisting of SEQ ID NOs: 1-26 and a LCVR selected from the group consisting of SEQ ID NOs: 27-53. Examples of pairings of HCVR and LCVR are provided throughout the present disclosure, but additional functional pairings are within the scope of the invention.

[0047] In some embodiments, the antibody comprises a HCVR having the sequence set forth in SEQ ID NO: 4 and a LCVR having the sequence set forth in SEQ ID NO: 28 (designated as 244C7 in Table 3); a HCVR having the sequence set forth in SEQ ID NO: 4 and a LCVR having the sequence set forth in SEQ ID NO: 27 (244C7m1); a HCVR having the sequence set forth in SEQ ID NO: 1 and a LCVR having the sequence set forth in SEQ ID NO: 28 (244C8); a HCVR having the sequence set forth in SEQ ID NO: 1 and a LCVR having the sequence set forth in SEQ ID NO: 27 (244C8m1); a HCVR having the sequence set forth in SEQ ID NO: 3 and a LCVR having the sequence set forth in SEQ ID NO: 31 (246F7); a HCVR having the sequence set forth in SEQ ID NO: 5 and a LCVR having the sequence set forth in SEQ ID NO: 44 (258C1); a HCVR having the sequence set forth in SEQ ID NO: 2 and a LCVR having the sequence set forth in SEQ ID NO: 30 (258F6); a HCVR having the sequence set forth in SEQ ID NO: 2 and a LCVR having the sequence set forth in SEQ ID NO: 29 (258F6m); a HCVR having the sequence set forth in SEQ ID NO: 6 and a LCVR having the sequence set forth in SEQ ID NO: 34 (392C4); a HCVR having the sequence set forth in SEQ ID NO: 7 and a LCVR having the sequence set forth in SEQ ID NO: 41 (394D5); a HCVR having the sequence set forth in SEQ ID NO: 8 and a LCVR having the sequence set forth in SEQ ID NO: 35 (394G1); a HCVR having the sequence set forth in SEQ ID NO: 12 and a LCVR having the sequence set forth in SEQ ID NO: 39 (388C12A); a HCVR having the sequence set forth in SEQ ID NO: 12 and a LCVR having the sequence set forth in SEQ ID NO: 32 (388C12B); a HCVR having the sequence set forth in SEQ ID NO: 13 and a LCVR having the sequence set forth in SEQ ID NO: 39 (388C16A); a HCVR having the sequence set forth in SEQ ID NO: 13 and a LCVR having the sequence set forth in SEQ ID NO: 32 (388C16B); a HCVR having the sequence set forth in SEQ ID NO: 9 and a LCVR having the sequence set forth in SEQ ID NO: 38 (392C5A); a HCVR having the sequence set forth in SEQ ID NO: 9 and a LCVR having the sequence set forth in SEQ ID NO: 37 (392C5B); a HCVR having the sequence set forth in SEQ ID NO: 17 and a LCVR having the sequence set forth in SEQ ID NO: 40 (392D2); a HCVR having the sequence set forth in SEQ ID NO: 16 and a LCVR having the sequence set forth in SEQ ID NO: 43 (392H4); a HCVR having the sequence set forth in SEQ ID NO: 20 and a LCVR having the sequence set forth in SEQ ID NO: 53 (246A10); a HCVR having the sequence set forth in SEQ ID NO: 18 and a LCVR having the sequence set forth in SEQ ID NO: 47 (388D4); a HCVR having the sequence set forth in SEQ ID NO: 19 and a LCVR having the sequence set forth in SEQ ID NO: 48 (392A6); a HCVR having the sequence set forth in SEQ ID NO: 21 and a LCVR having the sequence set forth in SEQ ID NO: 52 (411C2); a HCVR having the sequence set forth in SEQ ID NO: 22 and a LCVR having the sequence set forth in SEQ ID NO: 51 (413D2); or a HCVR having the sequence set forth in SEQ ID NO: 25 and a LCVR having the sequence set forth in SEQ ID NO: 45 (413E1).

[0048] In some embodiments, the antibody comprises a HCVR having the sequence set forth in SEQ ID NO: 20 and a LCVR having the sequence set forth in SEQ ID NO: 53 (246A10); a HCVR having the sequence set forth in SEQ ID NO: 25 and a LCVR having the sequence set forth in SEQ ID NO: 45 (413E1); a HCVR having the sequence set forth in SEQ ID NO: 22 and a LCVR having the sequence set forth in SEQ ID NO: 51 (413D2); a HCVR having the sequence set forth in SEQ ID NO: 18 and a LCVR having the sequence set forth in SEQ ID NO: 47 (388D4); a HCVR having the sequence set forth in SEQ ID NO: 1 and a LCVR having the sequence set forth in SEQ ID NO: 28 (244C8); or a HCVR having the sequence set forth in SEQ ID NO: 9 and a LCVR having the sequence set forth in SEQ ID NO: 38 (392C5A).

[0049] In some embodiments, the isolated antibody that binds to PD-1 binds to a sequence in PD-1 selected from the group consisting of SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, and SEQ ID NO: 84.

[0050] As used herein, an "antibody that binds to PD-1, comprising" a HCVR or LCVR, means an antibody comprising the HCVR or LCVR, as opposed to a PD-1 protein comprising the HCVR or LCVR.

[0051] In some embodiments, the antibody binds specifically to PD-1. This means that the antibody binds to PD-1

protein in a sample, with negligible binding to other proteins present in the sample, under a given set of binding reaction conditions.

[0052] Examples of antibody fragments include, a Fab, Fab', F(ab')₂, Fv, scFv, dAb, and a diabody.

[0053] A "Fab fragment" comprises one light chain and the C_H1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.

[0054] An "Fc" region contains two heavy chain fragments comprising the CH2 and CH3 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domains.

[0055] A "Fab' fragment" contains one light chain and a portion of one heavy chain that contains the VH domain and the CH1 domain and also the region between the CH1 and CH2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab' fragments to form a F(ab')₂ molecule.

[0056] A "F(ab')₂ fragment" contains two light chains and two heavy chains containing a portion of the constant region between the C_H1 and C_H2 domains, such that an interchain disulfide bond is formed between the two heavy chains. A F(ab')₂ fragment thus is composed of two Fab' fragments that are held together by a disulfide bond between the two heavy chains.

[0057] The "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions.

[0058] A "single-chain Fv antibody" (or "scFv antibody") refers to antibody fragments comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun (1994) *The Pharmacology Of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds. Springer-Verlag, New York, pp. 269-315. See also, PCT Publication No. WO 88/01649 and U.S. Pat. Nos. 4,946,778 and 5,260,203.

[0059] A "diabody" is a small antibody fragment with two antigen-binding sites. The fragments comprise a heavy chain variable region (VH) connected to a light chain variable region (VL) in the same polypeptide chain (VH-VL or VL-VH). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described in, e.g., patent documents EP 404,097; WO 93/11161; and Holliger et al. (1993) *Proc. Natl. Acad. Sci. USA* 90: 6444-6448.

[0060] A "domain antibody fragment" is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more VH regions are covalently joined with a peptide linker to create a bivalent domain antibody fragment. The two VH regions of a bivalent domain antibody fragment may target the same or different antigens.

[0061] In some embodiments, the antibody is modified or engineered. Examples of modified or engineered antibodies include chimeric antibodies, multiparatopic antibodies (e.g., biparatopic antibodies), and multispecific antibodies (e.g., bispecific antibodies).

[0062] As used herein, "multiparatopic antibody" means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigenic determinant on an antigen and at least one other single domain antibody is directed against a second antigenic determinant on the same antigen. Thus, for example, a "biparatopic" antibody comprises at least one single domain antibody directed against a first antigenic determinant on an antigen and at least one further single domain antibody directed against a second antigenic determinant on the same antigen.

[0063] As used herein, "multispecific antibody" means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigen and at least one other single domain antibody is directed against a second antigen (different from the first antigen). Thus, for example, a "bispecific" antibody is one that comprises at least one single domain antibody directed against a first antigen and at least one further single domain antibody directed against a second antigen, e.g., different from the first antigen.

[0064] In some embodiments, the antibodies disclosed herein are monoclonal antibodies, e.g., murine monoclonal antibodies. Methods of producing monoclonal antibodies are known in the art. See, for example, Pluckthun (1994) *The Pharmacology Of Monoclonal Antibodies*, Vol. 113, Rosenberg and Moore eds. Springer-Verlag, New York, pp. 269-315.

[0065] In some embodiments, antibodies are modified to reduce immunogenicity. When the antibodies are to be administered to a human, the antibodies can be "humanized" to reduce or eliminate antigenicity in humans. Accordingly, in some embodiments, the antibody comprises a humanized or human framework region (FR).

[0066] In some embodiments, the isolated antibody that binds to PD-1 comprises a HCVR selected from the group consisting of SEQ ID NOs: 85-90.

[0067] In some embodiments, the isolated antibody that binds to PD-1 comprises a LCVR selected from the group consisting of SEQ ID NOs: 91-96.

[0068] In certain embodiments, the isolated antibody that binds to PD-1 comprises a HCVR selected from the group consisting of SEQ ID NOs: 85-90 and a LCVR selected from the group consisting of SEQ ID NOs: 91-96. Examples of

pairings of HCVRs and LCVRs are provided throughout the present disclosure, but additional functional pairings are within the scope of the invention.

[0069] In some embodiments, the isolated antibody comprises a HCVR having the sequence set forth in SEQ ID NO: 90 and a LCVR having the sequence set forth in SEQ ID NO: 94; a HCVR having the sequence set forth in SEQ ID NO: 88 and a LCVR having the sequence set forth in SEQ ID NO: 96; a HCVR having the sequence set forth in SEQ ID NO: 90 and a LCVR having the sequence set forth in SEQ ID NO: 96; a HCVR having the sequence set forth in SEQ ID NO: 85 and a LCVR having the sequence set forth in SEQ ID NO: 91; a HCVR having the sequence set forth in SEQ ID NO: 85 and a LCVR having the sequence set forth in SEQ ID NO: 93; or a HCVR having the sequence set forth in SEQ ID NO: 86 and a LCVR having the sequence set forth in SEQ ID NO: 91.

[0070] Methods for reducing or eliminating the antigenicity of antibodies and antibody fragments are known in the art. In one approach, a nucleic acid encoding a PD-1 antibody disclosed herein is modified, for example, by replacing the mouse constant region with human heavy- and light-chain constant regions (e.g., U.S. Pat. No. 4,816,567; Morrison, et al., 1984, Proc. Natl. Acad. Sci. USA, 81:6851) to produce what is commonly referred to as a chimeric antibody.

[0071] A humanized antibody generally has one or more amino acid residues from a source that is non-human. The non-human amino acid residues are often referred to as "import" residues, and are typically taken from an "import" variable domain. Humanization can be performed generally following the method of Winter and co-workers (Jones et al., 1986, Nature 321:522-525; Riechmann et al., 1988, Nature, 332:323-327; Verhoeven et al., 1988, Science 239:1534-1536), by substituting non-human CDRs or CDR sequences for the corresponding sequences of a human antibody. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in non-human, for example, murine antibodies. Preferably, a humanized antibody has the same or substantially the same affinity for the antigen as the non-human, e.g., mouse antibody from which it was derived.

[0072] In an approach known as CDR grafting, the CDRs of the light and heavy chain variable regions are grafted into frameworks from another species. For example, murine CDRs can be grafted into human FRs. In some embodiments, the CDRs of the light and heavy chain variable regions of a PD-1 antibody are grafted into human FRs or consensus human FRs. To create consensus human FRs, FRs from several human heavy chain or light chain amino acid sequences are aligned to identify a consensus amino acid sequence. CDR grafting is described in, e.g., U.S. Pat. No. 7,022,500 (Queen); U.S. Pat. No. 6,982,321 (Winter); U.S. Pat. No. 6,180,370 (Queen); U.S. Pat. No. 6,054,297 (Carter); U.S. Pat. No. 5,693,762 (Queen); U.S. Pat. No. 5,859,205 (Adair); U.S. Pat. No. 5,693,761 (Queen); U.S. Pat. No. 5,565,332 (Hoogenboom); U.S. Pat. No. 5,585,089 (Queen); U.S. Pat. No. 5,530,101 (Queen); Jones et al. (1986) Nature 321: 522-525; Riechmann et al. (1988) Nature 332: 323-327; Verhoeven et al. (1988) Science 239: 1534-1536; and Winter (1998) FEBS Lett 430: 92-94.

[0073] The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence that is closest to that of the murine is then accepted as the FR for the humanized antibody (Sims et al., 1987, J. Immunol. 151:2296; Chothia et al., 1987, J. Mol. Biol. 196:901). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., 1992, Proc. Natl. Acad. Sci. USA 89:4285; Presta et al., 1993, J. Immunol. 151:2623).

[0074] It is important for humanized antibodies to retain affinity for the antigen and other desirable biological properties. To achieve this result, humanized antibodies can be designed analyzing parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs that illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences are available. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.

[0075] Other methods to reduce immunogenicity include "reshaping," "hyperchimerization," and "veneering/resurfacing." See, e.g., Vaswami et al., 1998, Ann. Allergy & Immunol. 81:105; Roguska et al., 1996, Prot. Engineer. 9:895-904; and U.S. Pat. No. 6,072,035 (Hardman). In the veneering/resurfacing approach, the surface accessible amino acid residues in the murine antibody are replaced by amino acid residues more frequently found at the same positions in a human antibody. This type of antibody resurfacing is described, e.g., in U.S. Pat. No. 5,639,641 (Pedersen).

[0076] Another approach for converting a mouse antibody into a form suitable for medical use in humans is known as ACTIVMAB™ technology (Vaccinex, Inc., Rochester, N.Y.), which involves use of a vaccinia virus-based vector to express antibodies in mammalian cells. High levels of combinatorial diversity of IgG heavy and light chains are said to be produced. See, e.g., U.S. Pat. No. 6,706,477 (Zauderer); U.S. Pat. No. 6,800,442 (Zauderer); and U.S. Pat. No.

6,872,518 (Zauderer).

[0077] Another approach for converting a mouse antibody into a form suitable for use in humans is technology practiced commercially by KaloBios Pharmaceuticals, Inc. (Palo Alto, CA). This technology involves the use of a proprietary human "acceptor" library to produce an "epitope focused" library for antibody selection.

[0078] Another approach for modifying a mouse antibody into a form suitable for medical use in humans is HUMAN ENGINEERING™ technology, which is practiced commercially by XOMA (US) LLC. See, e.g., PCT Publication No. WO 93/11794 and U.S. Pat. No. 5,766,886 (Studnicka); U.S. Pat. No. 5,770,196 (Studnicka); U.S. Pat. No. 5,821,123 (Studnicka); and U.S. Pat. No. 5,869,619 (Studnicka).

[0079] Humanization of antibodies is routine protein engineering. Nearly all murine antibodies can be humanized by CDR grafting, resulting in the retention of antigen binding. See, e.g., Lo, Benny, K. C., editor, in *Antibody Engineering: Methods and Protocols*, Vol. 248, Humana Press, New Jersey, 2004.

[0080] In some embodiments, the antibodies are antagonists. As used herein, "antagonist" in reference to an anti-PD-1 antibody means an antibody that inhibits the PD-1 signaling pathway in a cell (e.g., an immune cell). An antagonist anti-PD-1 antibody might inhibit the PD-1 signaling pathway by blocking the PD-1/PD-L1 or PD-1/PD-L2 interaction, but does not necessarily do so.

[0081] In some embodiments, the antibodies are agonists. As used herein, "agonist" in reference to an anti-PD-1 antibody means an antibody that activates the PD-1 signaling pathway in a cell (e.g., an immune cell). An agonist antibody might influence the PD-1/PD-L1 and/or PD-1/PD-L2 interaction, but does not necessarily do so.

[0082] An antibody that binds to PD-1 and competitively inhibits the binding of an antibody that contains one or more sequences disclosed herein is within the scope of the invention. In certain embodiments, the antibody competitively inhibits the binding of the antibody that comprises a HCVR having the sequence set forth in SEQ ID NO: 20 and a LCVR having the sequence set forth in SEQ ID NO: 53 (246A10); a HCVR having the sequence set forth in SEQ ID NO: 25 and a LCVR having the sequence set forth in SEQ ID NO: 45 (413E1); a HCVR having the sequence set forth in SEQ ID NO: 22 and a LCVR having the sequence set forth in SEQ ID NO: 51 (413D2); a HCVR having the sequence set forth in SEQ ID NO: 18 and a LCVR having the sequence set forth in SEQ ID NO: 47 (388D4); a HCVR having the sequence set forth in SEQ ID NO: 1 and a LCVR having the sequence set forth in SEQ ID NO: 28 (244C8). In some embodiments, the antibody also binds to a sequence in PD-1 selected from the group consisting of SEQ ID NOs: 54-84.

[0083] Methods for determining whether two or more antibodies compete for binding to the same target are known in the art. For example, a competitive binding, or competition, assay can be used to determine whether one antibody blocks the binding of another antibody to the target. Typically, a competition assay involves the use of purified target antigen (e.g., PD-1) bound to a solid substrate or expressed on cells, an unlabeled test binding molecule (e.g., a test anti-PD-1 antibody), and a labeled reference binding molecule (e.g., an antibody disclosed herein). Competitive inhibition is measured by determining the amount of label bound to the solid substrate or cells in the presence of the test molecule. Usually (but not necessarily) the molecule is present in excess of at least two-fold. A test antibody competes with the reference antibody or ligand (e.g., PD-L1 or PD-L2) for specific binding to the antigen if an excess of one antibody inhibits binding of the other antibody or ligand by at least 50%, as measured in a competition assay.

[0084] In an exemplary competition assay, a reference anti-PD-1 antibody (e.g., an antibody disclosed herein) is biotinylated using commercially available reagents. The biotinylated reference antibody is mixed with serial dilutions of the test antibody or unlabeled reference antibody (self-competition control) resulting in a mixture of various molar ratios of test antibody (or unlabeled reference antibody) to labeled reference antibody. The antibody mixture is added to a PD-1 coated-ELISA plate. The plate is then washed, and horseradish peroxidase (HRP)-streptavidin is added to the plate as the detection reagent. The amount of labeled reference antibody bound to the target antigen is detected following addition of a chromogenic substrate (e.g., TMB (3,3',5,5'-tetramethylbenzidine) or ABTS (2,2'-azino-di-(3-ethylbenzthiazoline-6-sulfonate)), which are known in the art. Optical density readings (OD units) are measured using a spectrophotometer. OD units corresponding to zero percent inhibition are determined from wells without any competing antibody. OD units corresponding to 100% inhibition, i.e., the assay background, are determined from wells without any labeled reference antibody or test antibody. Percent inhibition of labeled reference antibody to PD-1 by the test antibody (or the unlabeled reference antibody) at each concentration is calculated as follows: % inhibition = $(1 - (\text{OD units} - 100\% \text{ inhibition}) / (0\% \text{ inhibition} - 100\% \text{ inhibition})) * 100$. Persons skilled in the art will appreciate that the competition assay can be performed using various detection systems known in the art.

[0085] Antibodies identified by competition assay (e.g., competing antibodies) include antibodies binding to the same epitope, or similar (e.g., overlapping) epitopes, as the reference antibody. In addition, the competition assay can identify antibodies binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antibody for steric hindrance to occur.

[0086] Two antibodies bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody to the antigen reduce or eliminate binding of the other. Two antibodies bind to overlapping epitopes if only a subset of the amino acid mutations that reduce or eliminate binding of one antibody to the antigen reduce or eliminate binding of the other.

[0087] A competition assay may be conducted in both directions to ensure that the presence of the label does not interfere with or otherwise inhibit binding. For example, in the first direction, the reference antibody is labeled and the test antibody is unlabeled, and in the second direction, the test antibody is labeled and the reference antibody is unlabeled.

[0088] In certain embodiments, the present invention provides a method for increasing T cell effector function, comprising contacting a T cell with a combination of: (a) an effective amount of an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell; and (b) an effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell. In some embodiments, increasing T cell effector function includes, e.g., increased secretion of effector cytokines, as demonstrated herein.

[0089] In some embodiments, the T cell is contacted with the combination of antibodies *in vivo*. For example, in certain embodiments, the T cell is contacted with the combination in a human patient in need of increased T cell effector function.

[0090] In some embodiments, the present invention also provides a method for increasing T cell effector function, comprising contacting a T cell with an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell. In certain embodiments, the T cell is contacted with an antibody that comprises a heavy chain variable region having complementarity determining regions (CDRs) selected from the group consisting of CDRs 1-3 of SEQ ID NO:85, CDRs 1-3 of SEQ ID NO:86, and CDRs 1-3 of SEQ ID NO:87; and a light chain variable region having CDRs selected from the group consisting of CDRs 1-3 of SEQ ID NO:91, CDRs 1-3 of SEQ ID NO:92, and CDRs 1-3 of SEQ ID NO:93. In some embodiments, the T cell is contacted with an antibody that comprises a heavy chain variable region selected from the group consisting of SEQ ID NOS: 85, 86 and 87 and a light chain variable region selected from the group consisting of SEQ ID NOS: 91, 92 and 93. In certain embodiments, the T cell is contacted with an antibody that is selected from the group consisting of antibody 244C8-1, antibody 244C8-2 and antibody 244C8-3.

[0091] In some embodiments, the present invention provides a method for increasing lymphocyte secretion of a cytokine selected from the group consisting of IL-6, IL-12, IL-18, TNF- α , IL-1 β and GM-CSF in a human patient in need of increased T cell effector function, comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell. In certain embodiments, the patient is administered an antibody that comprises a heavy chain variable region having complementarity determining regions (CDRs) selected from the group consisting of CDRs 1-3 of SEQ ID NO:85, CDRs 1-3 of SEQ ID NO:86, and CDRs 1-3 of SEQ ID NO:87; and a light chain variable region having CDRs selected from the group consisting of CDRs 1-3 of SEQ ID NO:91, CDRs 1-3 of SEQ ID NO:92, and CDRs 1-3 of SEQ ID NO:93. In some embodiments, the patient is administered an antibody that comprises a heavy chain variable region selected from the group consisting of SEQ ID NOS: 85, 86 and 87 and a light chain variable region selected from the group consisting of SEQ ID NOS: 91, 92 and 93. In certain embodiments, the patient is administered an antibody that is selected from the group consisting of antibody 244C8-1, antibody 244C8-2 and antibody 244C8-3.

[0092] In some embodiments, the present invention also provides a method of treating cancer in a mammal, comprising contacting a T cell in a mammal in need thereof with a combination of: (a) an effective amount of an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell; and (b) an effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell.

[0093] The presently disclosed method of treating cancer with a combination of anti-PD-1 antibodies can be used to treat various cancers. In some embodiments, the cancer is selected from the group consisting of: melanoma, renal cancer, prostate cancer, pancreatic adenocarcinoma, breast cancer, colon cancer, lung cancer, esophageal cancer, squamous cell carcinoma of the head and neck, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, and lymphoma.

[0094] In some embodiments, the anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell is selected from the group consisting of: 388D4, nivolumab, pembrolizumab, EH12.2H7 and J105. In some embodiments, the anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell is 388D4.

[0095] In some embodiments, the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell is 244C8. In some embodiments, the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell binds to one or more of the following amino acid sequences: SEQ ID NO: 74, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 83 and SEQ ID NO: 84. In some embodiments, the anti-PD-1 antibody binds to all of the following amino acid sequences: SEQ ID NO: 74, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 83 and SEQ ID NO: 84. In some embodiments, the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell binds to a PD-1 epitope bound by 244C8. In some embodiments, the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell competes with 244C8 for binding to PD-1.

[0096] The presently disclosed method of treating cancer with an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of T cells, and an effective amount of an anti-PD-1 antibody that

does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cells, increases T cell effector function to a greater extent than an equivalent amount of either anti-PD-1 antibody alone. In some embodiments, the combination yields an additive effect on T cell effector function. In some embodiments, the combination yields a synergistic effect on T cell effector function.

[0097] The present invention provides isolated nucleic acids comprising a nucleotide sequence encoding a HCVR and/or a LCVR disclosed herein, or a fragment thereof. A nucleic acid according to the present invention may comprise DNA or RNA, and may be wholly or partially synthetic. For example, DNA molecules encoding an HCVR and/or LCVR disclosed herein can be chemically synthesized. Synthetic DNA molecules can be ligated to other appropriate nucleotide sequences, including, *e.g.*, constant region coding sequences, and expression control sequences, to produce conventional gene expression constructs encoding the desired antibodies. Production of defined gene constructs is within routine skill in the art. Alternatively, nucleotide sequences can be cloned out of hybridomas, for example, by conventional hybridization techniques or polymerase chain reaction (PCR) techniques, using synthetic nucleic acid probes or primers whose sequences are based on sequence information provided herein, or known sequence information regarding genes encoding the heavy and light chains of murine antibodies in hybridoma cells.

[0098] Techniques and protocols for engineering and production of nucleic acids are known in the art. *See, e.g.*, Current Protocols in Molecular Biology, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992.

[0099] A nucleotide sequence encoding an antibody of the invention can be operably linked to a promoter to effect expression of the antibody in a host cell. The sequence may include at its 5' end a leader sequence to facilitate expression in a host cell and/or secretion of the antibody from a host cell. Suitable leader sequences are known in the art and can be selected by the skilled person, taking account of the host cell.

[0100] In some embodiments, the nucleic acid is incorporated into a vector. Suitable vectors containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate, can be obtained commercially or constructed by persons of skill in the art. For further details *see, e.g.*, Molecular Cloning: a Laboratory Manual, 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Examples of vectors include plasmids, phages, phagemids, and cosmids, as well as transcription and expression cassettes.

[0101] Nucleic acids encoding a HCVR and/or a LCVR disclosed herein can be incorporated (ligated) into expression vectors, which can be introduced into host cells through conventional transfection or transformation techniques. Accordingly, a host cell can be transformed with an expression vector comprising a nucleotide sequence encoding a HCVR and/or a LCVR, or a fragment thereof. Examples of host cells include *E. coli* cells, Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK 293) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), and human hepatocellular carcinoma cells (*e.g.*, Hep G2).

[0102] Methods of producing an HCVR and/or LCVR, or a fragment thereof, disclosed herein are within the scope of the invention. In some embodiments, the method comprises:

- (a) growing a host cell containing an expression vector encoding the HCVR and/or LCVR under conditions so that the host cell expresses the antibody comprising the HCVR and/or LCVR, or a fragment thereof; and (b) isolating the antibody comprising the HCVR and/or LCVR, or a fragment thereof.

[0103] Suitable conditions for antibody expression and isolation or purification depend on the expression system employed. For example, if a gene is to be expressed in *E. coli*, it is first cloned into an expression vector by positioning the engineered gene downstream from a suitable bacterial promoter, *e.g.*, Trp or Tac, and a prokaryotic signal sequence. The expressed secreted protein accumulates in refractile or inclusion bodies, and can be harvested after disruption of the cells by French press or sonication. The refractile bodies then are solubilized, and the proteins refolded and cleaved by methods known in the art.

[0104] If the engineered gene is to be expressed in eukaryotic host cells, *e.g.*, CHO (Chinese hamster ovary) cells, it is first inserted into an expression vector containing a suitable eukaryotic promoter, a secretion signal, a poly A sequence, and a stop codon. Optionally, the vector or gene construct contains enhancers and introns. This expression vector optionally contains sequences encoding all or part of a constant region, enabling an entire, or a part of, a heavy or light chain to be expressed. The gene construct can be introduced into eukaryotic host cells using conventional techniques. The host cells express VL or VH fragments, VL-VH heterodimers, VH-VL or VL-VH single chain polypeptides, complete heavy or light immunoglobulin chains, or portions thereof, each of which may be attached to a moiety having another function (*e.g.*, cytotoxicity).

[0105] In some embodiments, a host cell is transfected with a single vector expressing a polypeptide expressing an entire, or part of, a heavy chain (*e.g.*, a heavy chain variable region) or a light chain (*e.g.*, a light chain variable region). In some embodiments, a host cell is transfected with a single vector encoding (a) a polypeptide comprising a heavy chain variable region and a polypeptide comprising a light chain variable region, or (b) an entire immunoglobulin heavy chain and an entire immunoglobulin light chain. In some embodiments, a host cell is co-transfected with more than one

expression vector (e.g., one expression vector expressing a polypeptide comprising an entire, or part of, a heavy chain or heavy chain variable region, and another expression vector expressing a polypeptide comprising an entire, or part of, a light chain or light chain variable region).

5 [0106] A polypeptide comprising an immunoglobulin heavy chain variable region or light chain variable region can be produced, for example, by growing (culturing) a host cell transfected with an expression vector encoding such a variable region, under conditions that permit expression of the polypeptide. Following expression, the polypeptide can be harvested and purified or isolated using techniques known in the art, e.g., affinity tags such as Protein A, Protein G, glutathione-S-transferase (GST), or histidine tags.

10 [0107] The antibodies of the present invention can be produced by growing (culturing) a host cell transfected with, for example: (a) an expression vector that encodes a complete or partial immunoglobulin heavy chain, and a separate expression vector that encodes a complete or partial immunoglobulin light chain; or (b) a single expression vector that encodes both chains (e.g., complete or partial heavy and light chains), under conditions that permit expression of both chains. The intact antibody (or antigen-binding fragment) can be harvested and purified or isolated using techniques known in the art, e.g., Protein A, Protein G, affinity tags such as glutathione-S-transferase (GST) or histidine tags. It is within ordinary skill in the art to express the heavy chain and the light chain from a single expression vector or from two separate expression vectors.

15 [0108] In some embodiments, anti-PD-1 antibodies are linked to a different functional molecule or moiety, e.g., a peptide, protein, toxin, radioisotope, or cytostatic agent, for various purposes such as *in vivo* diagnostic imaging or a diagnostic assay. The antibodies can be linked by chemical cross-linking or by recombinant methods. The antibodies also can be linked to any of various nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337. The antibodies can be chemically modified by covalent conjugation to a polymer, for example, to increase their circulating half-life. Examples of polymers and methods to attach them are described in U.S. Pat. Nos. 4,766,106; 4,179,337; 4,495,285; and 4,609,546.

25 **Pharmaceutical Formulations**

30 [0109] In some embodiments, the antibodies are formulated into pharmaceutical compositions suitable for administration to a mammal, e.g., a human patient. The compositions typically comprise one or more antibodies of the present invention and a pharmaceutically acceptable excipient. The term "pharmaceutically acceptable excipient" includes suitable solvents, dispersion media, coatings, antibacterial agents and antifungal agents, isotonic agents, and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art. The compositions also can contain other active compounds providing supplemental, additional, or enhanced therapeutic functions. The pharmaceutical compositions also can be included in a container, pack, or dispenser together with instructions for administration.

35 [0110] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Methods to accomplish the administration are known in the art. The administration may be, for example, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, intradermal, topical, inhalation, transmucosal, rectal or transdermal.

40 [0111] Solutions or suspensions used for intradermal or subcutaneous application typically include one or more of the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, as necessary. Such preparations may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

45 [0112] Pharmaceutical compositions suitable for injection include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes. For intravenous administration, suitable carriers include, for example, physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). Preferably, the pharmaceutical composition is stable under the conditions of manufacture and storage and is preserved against contamination by microorganisms such as bacteria and fungi. Avoidance of microorganisms can be achieved by inclusion of antibacterial and/or antifungal agents. Examples include: parabens, chlorbutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol such as glycerol, propylene glycol, liquid polyethylene glycol, and the like, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or

by the use of surfactants. Prolonged absorption of the injectable compositions can be achieved by including in the composition an agent that delays absorption, e.g., aluminum monostearate or gelatin.

[0113] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For oral administration, the antibodies can be combined with excipients and used in the form of tablets, troches, or capsules.

[0114] For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated can be used in the formulation. Such penetrants are known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration may be accomplished, for example, through the use of lozenges, nasal sprays, inhalers, or suppositories. For example, in case of antibodies that comprise the Fc portion, compositions may be capable of transmission across mucous membranes in intestine, mouth, or lungs (e.g., via the FcRn receptor-mediated pathway as described in U.S. Pat. No. 6,030,613). For transdermal administration, the active compounds may be formulated into ointments, salves, gels, or creams as generally known in the art. For administration by inhalation, the antibodies may be delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0115] In some embodiments, the presently disclosed antibodies are formulated with carriers that protect the antibody against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used. Exemplary polymers include ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions containing the presently disclosed antibodies can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known in the art. See, e.g., U.S. Pat. No. 4,522,811.

[0116] In some embodiments, pharmaceutical compositions contain, in addition to an antibody of the invention, a cytotoxic agent, cytostatic agent, anti-angiogenic agent, a tumor targeted agent, an immune stimulating agent or immune modulating agent, or an antibody conjugated to a cytotoxic, cytostatic, or otherwise toxic agent. The pharmaceutical composition optionally can be employed with other therapeutic modalities such as surgery, chemotherapy, and radiation.

[0117] Toxicity and therapeutic efficacy of the composition of the invention can be determined by conventional pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compositions that exhibit large therapeutic indices are preferred.

[0118] A therapeutically effective dose of a therapeutic antibody can be estimated initially, e.g., from cell culture assays. Examples of suitable bioassays include DNA replication assays, cytokine release assays, transcription-based assays, PD-1/PD-L1 binding assays, creatine kinase assays, assays based on the differentiation of pre-adipocytes, assays based on glucose uptake in adipocytes, immunological assays other assays as, for example, described in the Examples. The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the antibody that achieves a half-maximal inhibition of symptoms). Circulating levels in plasma may be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage lies preferably within a range of circulating concentrations with little or no toxicity. The dosage may vary depending upon the dosage form employed and the route of administration.

[0119] Generally, a therapeutically effective amount of an antibody or a composition described herein is in the range of 0.1 mg/kg to 100 mg/kg, preferably 0.1 mg/kg to 50 mg/kg. The amount administered will depend on variables such as the type and extent of disease or indication to be treated, the overall health of the patient, the *in vivo* potency of the antibody, the pharmaceutical formulation, the serum half-life of the antibody, and the route of administration.

[0120] Administration frequency can vary, depending on factors such as route of administration, dosage amount, serum half-life of the antibody or fusion protein, and the disease being treated.

Therapeutic Uses

[0121] The invention provides methods of treating PD-1-mediated diseases or disorders in a mammal, e.g., a human patient, comprising administering an effective amount of an antibody of the present invention to a mammal in need thereof. In some embodiments, the method is a method of treating cancer. In some embodiments, the method is a method of treating inflammation. In some embodiments, the method is a method of treating an autoimmune disease, e.g., Crohn's disease.

[0122] As used herein, "treat", "treating" or "treatment" means inhibiting or relieving a disease or disorder. For example, treatment can include a postponement of development of the symptoms associated with a disease or disorder, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease. The terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes

of such symptoms. Thus, the terms denote that a beneficial result is being conferred on at least some of the mammals, e.g., human patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment.

[0123] As used herein, the term "effective amount" means an amount of an anti-PD-1 antibody, that when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective to achieve the desired therapeutic or prophylactic effect under the conditions of administration. For example, an effective amount is one that would be sufficient to enhance or diminish the immune response to bring about effectiveness of a therapy. The effectiveness of a therapy (e.g., activation of a suppressed or deficient immune response, increased cytolytic activity of T cells, increased T cell effector function, alteration of PD-1 activity associated with the negative regulation of T-cell mediated immune response, or reduction in tumor growth) can be determined by suitable methods known in the art.

[0124] When used to treat cancer, antibodies of the invention can be used alone or in combination with another therapeutic agent. Examples of other therapeutic agents include other checkpoint inhibitors, immunogenic agents, attenuated cancerous cells, tumor antigens (e.g., recombinant proteins, peptides, and carbohydrate molecules), antigen presenting cells such as dendritic cells pulsed with tumor-derived antigen or nucleic acids, immune stimulating cytokines (e.g., IL-2, IFN α 2, GM-CSF), and cells transfected with a gene encoding an immune stimulating cytokine (e.g., GM-CSF); chemotherapy, radiotherapy, and surgery.

[0125] In some embodiments, an antibody of the invention is administered to a cancer patient in combination with another checkpoint inhibitor. The other checkpoint inhibitor can be targeted against PD-1 or against a different checkpoint molecule, e.g., TIM3, CEACAM1, TIGIT, LAG3 or VISTA. The other checkpoint inhibitor can be a small molecule or a monoclonal antibody. When the other checkpoint inhibitor is a second PD-1 inhibitor, preferably, the mechanism of action of the second PD-1 inhibitor differs from the mechanism of action of the first PD-1 inhibitor. For example, the two PD-1 inhibitors can be two anti-PD-1 monoclonal antibodies that bind to different epitopes on the PD-1 molecule.

[0126] When used to treat cancer, antibodies of the invention can be used alone or in combination with other checkpoint inhibitors, anti-neoplastic agents or immunogenic agents. Examples include attenuated cancerous cells, tumor antigens (including, e.g., recombinant proteins, peptides, and carbohydrate molecules), antigen presenting cells such as dendritic cells pulsed with tumor-derived antigen or nucleic acids, immune stimulating cytokines (e.g., IL-2, IFN α 2, GM-CSF), and cells transfected with genes encoding immune stimulating cytokines (e.g., GM-CSF; cancer treatments such as chemotherapy, radiotherapy, and surgery).

[0127] In treating certain diseases or disorders, it is desirable to diminish or suppress a patient's immune response, at least in certain tissues of the body. Such diseases and disorders include allergies and various autoimmune diseases. Examples of autoimmune diseases include rheumatoid arthritis, type I diabetes mellitus, multiple sclerosis, inflammatory bowel disease, Crohn's disease, and systemic lupus erythematosus, Hashimoto's thyroiditis, ankylosing spondylitis, and graft-versus-host disease (GVHD). It is also desirable to suppress a patient's immune response to avoid transplant rejection following tissue, skin or organ transplant.

[0128] In some embodiments, anti-PD-1 antibodies of the invention are administered with one or more additional therapeutic agents, e.g., a cytotoxic agent, a radiotoxic agent, or an immunosuppressive agent. The antibody can be linked to the agent (as an immunocomplex) or administered separately. In some embodiments, the additional therapeutic agent is an immunomodulatory agent or an anti-cancer agent (e.g., a chemotherapeutic agent). In separate administration, the antibody can be administered before, after or concurrently with the agent or can be co-administered with other known therapies. Combination therapies are known in the art. See, e.g., Hardman, et al. (eds.) (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill, New York, N.Y.; Poole and Peterson (eds.) (2001) Pharmacotherapeutics for Advanced Practice: A Practical Approach, Lippincott, Williams & Wilkins, Phila., PA; Chabner and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy, Lippincott, Williams & Wilkins, Philadelphia, PA.

[0129] In some embodiments, an antibody disclosed herein is used as a targeting agent for delivery of a payload, e.g., a toxin, to a cell expressing PD-1. The method includes administering an anti-PD-1 antibody conjugated to a payload moiety. Suitable conjugation methods are known in the art.

Non-therapeutic Uses

[0130] In some embodiments, antibodies of the invention are used for non-therapeutic purposes, such as diagnostic tests and assays. For example, the invention provides a method of diagnosing a PD-1-mediated adaptive immune resistance in a patient who has cancer. The method comprises contacting a tumor microenvironment in the patient with an antibody disclosed herein that has been labeled with a detectable moiety; and detecting expression of PD-1 on immune cells, e.g., CD8+ T cells; B cells; and macrophages, within the tumor microenvironment.

[0131] Adaptive immune resistance includes suppression of a host immune response as a result of activation of a PD-1 signaling pathway in immune cells of the host. For example, cancer tissue suppresses a host immune response by upregulation of PD-L1 and its binding to PD-1 on immune cells on T cells (such as CD8+ T cells); B cells; and macrophages.

[0132] A diagnostic method utilizing an antibody of the invention to detect PD-1 expression also can comprise an

agent for detecting expression of PD-L1 on immune cells within the tumor microenvironment. Such a diagnostic method can be performed *in vivo*, or on a biopsy sample from a patient, wherein the tumor microenvironment is present in a tumor biopsy.

[0133] Modifications of antibodies for diagnostic purposes are well known in the art. For example, antibodies may be modified with a ligand group such as biotin, or a detectable marker group such as a fluorescent group, a radioisotope, or an enzyme. Antibodies of the invention can be labeled using conventional techniques. Suitable detectable labels include: fluorophores, chromophores, radioactive atoms, electron-dense reagents, enzymes, and ligands having specific binding partners. Enzymes typically are detected by their reaction products. For example, horseradish peroxidase can be detected through conversion of tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a spectrophotometer. For detection, suitable binding partners include biotin and avidin or streptavidin, IgG and protein A, and the numerous receptor-ligand couples known in the art. Other permutations and possibilities will be readily apparent to those of ordinary skill in the art.

[0134] Antibodies of the invention also can be used to detect the presence of PD-1 in biological samples. The amount of PD-1 detected can be correlated with the expression level of PD-1, which, in turn, is correlated with the activation status of immune cells, e.g., activated T cells, B cells, and monocytes, in the subject.

[0135] Detection methods that employ antibodies are known in the art, and include ELISA, radioimmunoassay, immunoblot, Western blot, immunofluorescence, and immunoprecipitation techniques. Antibodies of the invention can be provided in a diagnostic kit that incorporates one or more of these techniques to detect PD-1. Such a kit may contain other components, packaging, instructions, or material to aid in the detection of PD-1 protein.

EXAMPLES

[0136] The following Examples are merely illustrative, and are not intended to limit the scope or content of the invention in any way.

Example 1. Identification of PD-1 Antibodies

A. Immunization of Mice with PD-1

[0137] Balb/C, C57BL/6 or NZW/B female mice aged 4-8 weeks were immunized in a standard prime/boost regimen employing standard adjuvant mixtures. A soluble extracellular domain of human PD-1 (AA1-167) expressed with a C-terminal polyhistidine sequence (SinoBiological #10377-H08H) was used for immunizations. Cohorts of mice were primed with 50 μ g of recombinant PD-1 and (1) complete Freund's adjuvant (Sigma-Aldrich #263810) or (2) alhydrogel (InvivoGen). Two to three weeks later, animals in each group were boosted with 50 μ g of soluble PD-1 with (1) incomplete Freund's adjuvant (Sigma-Aldrich #263910) or (2) alhydrogel. Serum titres were collected after each antigen boost and assayed by ELISA for reactivity and antibody isotype class switching. The same protein used for immunizations was immobilized onto 96 well assay plates (Nunc MAXISORP) at a concentration of 1 μ g/mL. Serial dilutions of the sera from immunized animals were then tested for binding to PD-1.

B. Screening of Antibodies for Binding to Human PD-1

[0138] Cells, fresh or thawed from cryopreserved samples, from bone marrow, lymph nodes or the spleen were carried in standard tissue culture medium (LifeTech RPMI with 10% low IgG). Cells were interrogated for antigen-specific B cells, unstimulated or stimulated, using LPS (InvivoGen) at a concentration of 20 ng/mL. Cells, unstimulated or stimulated, were then loaded at a stochastic cellular density to favor single cell per well loading onto microwell arrays (MWAs) as described in U.S. Patent Nos. 7,776,553 and 8,772,049.

[0139] A functionalized capture surface, coated with two mixtures of polyclonal anti-mouse IgG antibodies (Jackson ImmunoResearch #715-005-150, #115-005-146), was then used to hermetically seal the ordered microwell array. After two hours, the capture surface(s) was removed from the microdevices and processed as described previously (Ogunnyi et al. Nature Protocols, 2009). The microarray capture surface, representing a mirror image of the cells in the microwell array, contained the secreted output of the B cells. The antibodies secreted by the B cells in nanowells and captured were then assayed for reactivity against human PD-1, or an unrelated antigen, and also assayed for IgG versus IgM reactivity (JacksonImmunoResearch #115-005-044, #115-005-164).

[0140] After the protein microarrays were scanned, putative antibody clones with the desired specificity and antibody isotype class were bioinformatically identified by standard data quality metrics. According to methods previously described (Ogunnyi et al., Vaccine 2014), microarray images were analyzed using Molecular Devices GenePix software. Microarray features were analyzed for false positivity, co-variance, and signal-to-noise ratios. Features with the correct attributes, e.g., specific for PD-1 and IgG, were then nominated for cellular retrieval. This automated pick-list was then generated

from 4 to 12 microdevices, and cells that had secreted antibodies with desired characteristics were isolated from the microdevices and placed into standard SBS microtitre assay plates for further processing.

C. Isolation of Antibodies that Bind PD-1

[0141] Single antibody-producing cells identified from screening were used for single cell molecular biology in order to isolate the genetic sequences encoding antibody heavy and light chains (Tiller et al., J. Immunol. Methods 350:183-93 (2009)). The genes encoding the specific antibodies that recognize human PD-1 were retrieved using single cell RT-PCR. Retrieved cells were placed into reverse transcription buffer, and the mRNA from each individual cell was reverse transcribed (LifeTech SuperScript III) into cDNA. After generating these amplicons by standard nested polymerase chain reaction(s) (PCR), these amplicons were subjected to direct sequencing. After analysis by Phred software using a Phred 0.05 cut-off value, sequences were sub-cloned into PCR 2.1 (LifeTech) or other standard vector backbones for further propagation. Phred is software that reads DNA sequencing trace files, calls bases, and assigns a quality value to each called base. See, e.g., Ewing and Green, Genome Research 8:186-94 (1998).

[0142] These DNA sequences were then bioinformatically filtered for sequence quality and organized into a sequence database for cladistics analysis (distance or parsimony), in order to identify how many unique antibody clades were isolated that recognize PD-1. These analyses identified approximately 20 unique clades (groups) of sequences that recognize human PD-1.

D. Antibody Construction

[0143] Complete antibody variable regions comprising a pair of heavy and light chain variable regions (Tables 1 and 2) were reformatted into plasmids with the proper elements for transient ectopic expression in mammalian cell lines, e.g., HEK293 or CHO, using standard molecular biology techniques. For example, the variable heavy (VH) and variable light (VL) cDNA sequences were sub-cloned into the vector backbone pFUSE-CHlg-mG1 (InVivoGen), which contains an IL2 signal sequence, as well as an in-frame murine Fc-domain. A sequence verified consensus sequence for each antibody VH and VL gene was engineered, using PCR primers, with restriction sites. The expression vector of choice and the PCR amplicons were then digested with restriction enzymes and then ligated together for transformation of *E. Coli*. Resulting expression clones were sequence verified.

[0144] The sequences of the individual heavy chain and light chain variable regions are shown in FIG. 1 (HCVR) and FIG. 2 (LCVR). The complementarity determining regions (CDRs) and framework regions (FRs) are indicated. Tables 1 and 2 list each HCVR or LCVR by clone name and corresponding sequence identifier. The corresponding sequences are shown in FIGS. 1 and 2.

Table 1. Heavy Chain Variable Region Sequence Designations and Identifiers

Heavy Chain Variatle Region	SEQ ID NO:
100244_C8VH3	1
100258_F6VH4	2
100246_F7VH3	3
100244_C7VH10	4
100258_C1VH4	5
100392_C4VH5	6
100394_DSVH9	7
100394_G1VH1	8
100392_C5VH6	9
100392_H3VH6	10
100394_F1VH8	11
100388_C1VH2	12
100388_C1VH6	13

EP 3 916 017 A1

(continued)

5

10

15

20

Heavy Chain Variable Region	SEQ ID NO:
100388_G1VH5	14
100392_B4VH10	15
100392_H4VH9	16
100392_D2VH7	17
100388_D4VH3	18
100392_A6VH8	19
100246_A10VH1	20
100411_C2VH3	21
100413_D2VH9	22
100388_H4VH1	23
100392_C3VH7	24
100413_E1VH9	25
100413_H1VH3	26

25

Table 2. Light Chain Variable Region Sequence Designations and Identifiers

30

35

40

45

50

55

Light Chain Variable Region	SEQ ID NO:
100245_C8VK5m1)	27
100245_C8VK5	28
100259_F6VK1m1	29
100259_F6VK1	30
100247_F7VK2	31
100389_C1VK2	32
100395_F1VK4	33
100393_C4VK8	34
100395_G1VK4	35
100389_G1VK1	36
100393_C5VK10	37
100393_C5VK7	38
100389_C1VK1	39
100393_D2VK6	40
100395_D5VK7	41
100393_H3VK2	42
100393_B4VK10/H4VK6	43
100259_C1VK1	44
100414_E1VK5	45
100414_H1VK6	46
100389_D4VK5	47

(continued)

Light Chain Variable Region	SEQ ID NO:
100393_A6VK5	48
100389_H4VK4	49
100393_C3VK10	50
100414_D2VK6	51
100412_C2VK7	52
100247_A10VK3	53

Example 2. Antibody Characterization

A. Hit Confirmation and Specificity

[0145] Supernatants from transiently transfected mammalian cell lines were used to test for immunoglobulin (Ig) expression, antigen specificity, and antigen affinity. These assays were ELISA-based, using reagents that recognize IgG, as well as the soluble ECD of PD-1 as an Fc-fusion protein (SinoBiological "CD279-Fc"). While the screening immunogen was the soluble form of PD-1, the form used for binding confirmation was a fusion protein comprising the ECD of human PD-1 with a human Fc domain. Other immune checkpoint proteins in the same biochemical configurations were used as specificity controls, e.g., CD28, GITR. Proteins were immobilized in wells of a 96 well assay plate (Nunc MAXISORB) and supernatants from transfected HEK293 cells were used to assess binding of reformatted anti-PD-1 antibodies, produced as described above. These experiments enabled determination of binding specificity and affinity.

[0146] FIG. 3 shows an example of an ELISA-based binding assay. Various VH and VK were paired to yield 32 clones (clone pairings shown in box of FIG. 3), which were expressed in HEK293 cells and assayed for binding to PD-1-HIS(tag). The results represent an average of two experiments.

B. Cellular Binding

[0147] Recombinant antibodies from cultured supernatants were also used in cell-based binding studies. HEK293 cells were transfected (Qiagen, SuperFect) with expression plasmids encoding the Ig heavy and light chains of anti-PD-1 antibodies. After 3-5 days, recombinant antibodies in the supernatants of transfected cells were harvested. Stable HEK293 cells expressing human PD-1 or primary cells were used for the cell-based binding confirmation studies. Antibodies from cultured supernatants were assessed for binding to cell surface PD-1 using fluorescently labeled anti-mouse IgG (polyclonal) antibody (Jackson Immunoresearch).

[0148] Fluorescence microscopy studies revealed that a number of anti-PD-1 antibodies obtained from transfection supernatants bound to PD-1 expressed on the surface of HEK293 cells. Binding of four mouse anti-PD-1 antibodies including, 100244_C7VH10_100245_C8VK5m1 (comprising the HCVR corresponding to SEQ ID NO: 4 and LCVR corresponding to SEQ ID NO: 27), were detected with anti-mouse κ -PE (secondary antibody). Similarly, in a separate study, binding of five mouse anti-PD-1 antibodies including, 100392_C5VH6_100393_C5VK7, comprising the HCVR corresponding to SEQ ID NO: 9 and LCVR corresponding to SEQ ID NO: 38, were detected with anti-mouse IgG1-AF488 (secondary antibody). In both studies, commercially available mouse anti-PD-1 antibody and isotype control mouse IgG1 anti-PD-1 were used as controls.

[0149] Table 3 summarizes results of tests of binding of various anti-PD-1 antibodies to PD-1 expressed on the surface of HEK293 cells. Strong binding is denoted as "+++", medium binding is denoted as "++", and weak binding is denoted as "+".

Table 3. Summary of PD-1 mAb binding to cell-surface expressed PD-1

Mouse anti-human PD-1 Abs	Binding to Human PD-1 Expressed on HEK293 Surface	mAb Name
100244_C7VH10_100245_C8VK5	++	244C7
100244_C7VH10_100245_C8VK5m1	++	244C7m1
100244_C8VH3_100245_C8VK5	++	244C8
100244_C8VH3_100245_C8VK5m1	++	244C8m1

EP 3 916 017 A1

(continued)

	Mouse anti-human PD-1 Abs	Binding to Human PD-1 Expressed on HEK293 Surface	mAb Name
5	100246_F7VH3_100247_F7VK2	++	246F7
	100258_C1VH4_100259_C1VK1	+	258C1
	100258_F6VH4_100259_F6VK1	++	258F6
	100258_F6VH4_100259_F6VK1m1	++	258F6m
10	100392_C4VH5_100393_C4VK8	+++	392C4
	100394_D5VH9_100395_D5VK7	++	394D5
	100394_G1VH1_100395_G1VK4	++	394G1
15	100388_C1VH2_100389_C1VK1	++	388C12A
	100388_C1VH2_100389_C1VK2	++	388C12B
	100388_C1VH6_10038_C1VK1	++	388C16A
	100388_C1VH6_100389_C1VK2	++	388C16B
20	100388_G1VH5_100389_G1VK1	-	388G1
	100392_B4VH10_100393_B4VK10	-	392B4
	100392_C5VH6_100393_C5VK7	++	392C5A
25	100392_C5VH6_100393_C5VK10	++	392C5B
	100392_D2VH7_100393_D2VK6	++	392D2
	100392_H3VH6_100393_H3VK2	-	392H3
	100392_H4VH9_100393_H4VK6	+	392H4
30	100394_F1VH8_100395_F1VK4	-	394F1
	100246_A10VH1_100247_A10VK3	+++	246A10
	100388_D4VH3_100389_D4VK5	+++	388D4
35	100388_H4VH1_100389_H4VK4	-	388H4
	100392_A6VH8_100393_A6VK5	++	392A6
	100392_C3VH7_100393_C3VK10	-	392C3
40	100411_C2VH3_100412_C2VK7	++	411C2
	100413_D2VH9_100414_D2VK6	++	413D2
	100413_E1VH9_100414_E1VK5	++	413E1
	100413_H1VH3_100414_H1VK6	-	413H1
45	mouse anti-PD-1 cl. EH12.2H7 (1 μg/mL)	++	n/a
	isotype control mouse IgG1 (1 μg/mL)	-	n/a

C. Cell-based Activity

50 **[0150]** Antibodies that recognize PD-1 with high affinity were selected for use in cell-based assays to test for agonist and antagonist activity. Using standard *ex vivo* activation conditions with primary human cells, selected anti-PD-1 antibodies were used for cell-based assays in microwell array devices, using conditions that have been previously characterized (see, e.g., Varadarajan et al., 2012, Proc. Nat'l Acad. Sci. 109:3885-3890) to assess effects of these antibodies on effector cell function.

55 **[0151]** Peripheral blood mononuclear cells (PBMCs) obtained from de-identified donors via a commercial source were used in these studies. PBMCs were placed into wells of a 96-well assay plate previously coated with plate bound anti-CD3 (OKT3) at a concentration of 1 μg/mL. In addition to TCR-mediated stimulation, cells were treated with PBS (control),

soluble recombinant human PD-L1 (shPD-L1) (SinoBiological) at 20 $\mu\text{g/mL}$, or shPD-L1 with anti-PD-1 antibody (10 $\mu\text{g/mL}$). Cellular proliferation was assayed by ELISA for IL-2 (R&D Systems, #D2050) in the supernatant of cell cultures, or by direct measurement of secreted IFN γ at the single cell level (Varadarajan, *supra*) using microwell array devices.

[0152] FIG. 4 summarizes results from assays to measure the effectiveness of anti-PD-1 antibodies in relieving PD-L1 dependent inhibition of activation of human peripheral blood mononuclear cells (PBMCs). Treatments of cells were carried out in 96-well plates for 3-5 days. All treatments included plate-bound CD3 and soluble CD28 in conventional media. Cells were treated additionally with nothing (positive control); with PD-L1 alone; or with PD-L1 plus an anti-PD-1 antibody (EH12.2H7 (BioLegend Products, San Diego, CA), j 105 (eBioscience, San Diego, CA), pembrolizumab, 246A10 or 244C8). At the end of the treatment period, cells were transferred to a microwell array device for IFN γ determination at the level of individual cells, with sample cell populations in the range of approximately 50-100 cells. The results shown in FIG.4 illustrate antagonism of PD-1 activity by anti-PD-1 antibodies. These anti-PD-1 antibodies blocked the inhibitory effect of PD-L1, thus decreasing PD-1/PD-L1 (or PD-1/PD-L2) mediated inhibition of cellular immune response.

D. Differential T Cell Activation

[0153] In a first type of cell-based activation assay, commercially-sourced human PBMCs (peripheral blood mononuclear cells) (Research Blood Components, Allston, MA) were analyzed by flow cytometry to test for differential T cell activation in response to PD-1 blockade by different anti-PD-1 antibodies *in vitro*. CD4 and CD8 were used as T cell markers. The relative extent of T cell activation was inferred from measuring production of the effector cytokines, interferon gamma (IFN γ) and tumor necrosis factor-alpha (TNF α). The experiments were conducted essentially as follows. Approximately 500,000 to 750,000 PBMCs were incubated for three days in the presence of 1 $\mu\text{g/mL}$ anti-CD3 (clone HIT3a), 50 ng/mL anti-CD28 (clone CD28.2) and 20 $\mu\text{g/mL}$ anti-PD-1 antibody or isotype control. At the end of the 3-day incubation period, cells were treated with Brefeldin A for 6 hours and then subjected to extracellular staining for CD4, CD8, CD69, CD25, PD-L1, or other extracellular markers conjugated to fluorophores. Cells were then fixed, permeabilized, and stained for intracellular markers including IFN γ (antibody clone 4S.B3). Data were collected by flow cytometry using a FACSCALIBUR™ flow cytometer (Becton Dickinson, Franklin Lakes, NJ), and analyzed using FLOW-JO™ software (FlowJo, LLC, Ashland, OR). The antibodies tested were pembrolizumab, clone EH12.2H7 (BioLegend), and anti-PD-1 antibodies 388D4, 413E1, 246A10 and 244C8 of the present invention. Under conditions of suboptimal activation (achieved by the treatment with anti-CD3 and anti-CD28), which may mimic activation conditions that occur *in vivo*, antibodies 388D4, 413E1, 246A10 and 244C8 in these tests elicited similar secretion levels, or enhanced secretion levels of IFN γ and TNF α , as compared to EH12.2H7 or pembrolizumab (Table 4). The data in Table 4 are compared graphically in FIG. 5.

Table 4. Summary of differential T cell activation in response to PD-1 blockade by different anti-PD-1 antibodies

	CD8 IFN γ % positive	CD4 IFN γ % positive	CD8 TNF α % positive
Negative control	4.6	1.64	3.73
CD3/CD28	18.2	6.31	6.19
pembrolizumab	28.4	14.1	13
388D4	31.2	21.2	8.56
413E1	27	20.2	11.1
246A10	26.2	20.3	14.9
244C8	19.9	9.64	14.5
EH12.2H7	19.5	12.8	14.1
Positive control	73.7	61.5	37.3

[0154] In a second set of experiments, human PBMCs were tested for reactivity in antigen recall assays using CMV (cytomegalovirus) (IMMUNOSPOT®, Shaker Heights, OH). PBMCs were purified from whole blood of healthy donors (Research Blood Components, Allston, MA). The PBMCs were incubated with ready-to-use peptide antigen solutions (Astarte Biologics, Bothell, WA) without or with anti-PD-1 antibodies. Two commercial stage anti-PD-1 antibodies, pembrolizumab and nivolumab, were used as benchmarks for this experiment. Compared to antibody isotype control(s), anti-PD-1 antibodies induce increased levels of IFN γ , a key effector cytokine in T cell antigen recall biology (FIG. 6).

[0155] In a third set of experiments, anti-PD-1 antibodies were used with PBMCs in MLR (mixed lymphocyte reaction)

EP 3 916 017 A1

assays. In these assays, secretion of IL-2 or IFN γ was the experimental cytokine readout (FIG. 7A). Activation markers such as CD25 were also evaluated (FIG. 7B). Results are summarized in FIGS. 7A and 7B. In this assay, clone 388D4 appears to induce cytokine release and CD25 upregulation similar to nivolumab. In multiple assays, clone 244C8 appears to induce increased levels of cytokine release (IFN γ) compared with 388D4 or nivolumab. T cells incubated with 244C8 also appear to exhibit a higher degree of activation as inferred from CD25 expression (FIG. 7B).

[0156] These data indicate that some of the anti-PD-1 antibodies of the present invention, e.g., 388D4, induce increased cytokine release in a manner similar to pembrolizumab and nivolumab, while other antibodies, e.g., 244C8, elicit physiological responses that are measurably different from the responses elicited by pembrolizumab and nivolumab.

E. Peptide-based epitope mapping

[0157] Synthetic overlapping peptides based on the human PD-1 sequence (15-mers) (Sigma-Aldrich PEPscreen, Saint Louis, MO) were used in epitope mapping experiments. The peptides used are listed in Table 5 below.

Table 5. Human PD-1 peptide sequences used for epitope mapping

Peptide Name	N-term mod	Sequence	C-term Mod	SEQ ID NO:
PD101	[H]	MQIPQAPWPVWAVL	[OH]	54
PD102	[H]	APWPVWAVLQLGWR	[OH]	55
PD103	[H]	VWAVLQLGWRPGWFL	[OH]	56
PD104	[H]	QLGWRPGWFLDSPDR	[OH]	57
PD105	[H]	PGWFLDSPRPWNPP	[OH]	58
PD106	[H]	DSPDRPWNPPTFSPA	[OH]	59
PD107	[H]	PWNPPTFSPALLVVT	[OH]	60
PD108	[H]	TFSPALLVTEGDNA	[OH]	61
PD109	[H]	LLVTEGDNATFTCS	[OH]	62
PD110	[H]	EGDNATFTCSFSNTS	[OH]	63
PD111	[H]	TFTCSFSNTSEFVL	[OH]	64
PD112	[H]	FSNTSEFVLNWYRM	[OH]	65
PD113	[H]	ESFVLNWYRMSPSNQ	[OH]	66
PD114	[H]	NWYRMSPSNQTDKLA	[OH]	67
PD115	[H]	SPSNQTDKLAAFPED	[OH]	68
PD116	[H]	TDKLAAFPEDRSQPG	[OH]	69
PD117	[H]	AFPEDRSQPGQDCRF	[OH]	70
PD118	[H]	RSQPGQDCRFRTQL	[OH]	71
PD119	[H]	QDCRFRTQLPNGRD	[OH]	72
PD120	[H]	RVTQLPNGRDFHMSV	[OH]	73
PD121	[H]	PNGRDFHMSVVRARR	[OH]	74
PD122	[H]	FHMSVVRARRNDSGT	[OH]	75
PD123	[H]	VRARRNDSGTLYCGA	[OH]	76
PD124	[H]	NDSGTLYCGAISLAP	[OH]	77
PD125	[H]	YLCGAISLAPKAQIK	[OH]	78
PD126	[H]	ISLAPKAQIKESLRA	[OH]	79
PD127	[H]	KAQIKESLRAELRVT	[OH]	80
PD128	[H]	ESLRAELRVTERRAE	[OH]	81

EP 3 916 017 A1

(continued)

Peptide Name	N-term mod	Sequence	C-term Mod	SEQ ID NO:
PD129	[H]	ELRVTERRAEVPTAH	[OH]	82
PD130	[H]	ERRAEVPTAHPSPSP	[OH]	83
PD131	[H]	VPTAHPSPSPRPAGQF	[OH]	84

[0158] Each peptide was incubated with each antibody for one hour, to allow peptide-antibody complex formation. Then each of these antibody-peptide mixtures was used in a conventional ELISA, in which human PD-1 was immobilized on 96-well plates. ELISA plates were coated with 100 ng/well of PD-1-His Tag (Sino Biological, North Wales, PA; #10377-H08H-50) in carbonate buffer, pH 9.6. After washing, plates were blocked with 4% milk PBS, 0.05% Tween-PBS (blocking buffer). After blocking and washing of the plates, the peptide-antibody mixtures were incubated with the immobilized human PD-1. After washing, the plates were developed by incubation for 1 hour with goat HRP-conjugated anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA; #115-035-071) and addition of 100 μ l of TMB solution (ThermoScientific, Waltham, MA; #PI-34022). Optical densities were measured at the appropriate wavelength, using an ELISA microplate reader. This enabled quantitative assessment of which peptides complexed with the antibody and then inhibited antibody binding to human PD-1. FIG. 8 summarizes the binding results of five antibody clones (246A10, 244C8, 388D4, 413D2, and 413E1).

F. Biophysical characterization of anti-PD-1 antibodies

[0159] Biophysical characteristics of certain anti-PD-1 antibodies were analyzed by biolayer interferometry (BLI), using the ForteBio Octet Red system (Pall Corporation, Menlo Park, CA). The antibodies were immobilized on BLI biosensors and then incubated with the soluble extracellular domain of human PD-1. Using standard biophysics methods, apparent on-rates and off-rates were then inferred for PD-1 with anti-PD-1 antibodies. These values were used to generate apparent affinity values (K_D values), which are listed in Table 6.

Table 6.

IgG	K_D (nM)	k_{on} (1/Ms)	k_{dis} (1/s)	R_{max}	Full X^2	Full R^2
246A10	76.4	1.61×10^5	1.23×10^{-2}	0.10	0.01	0.99
244C8	15.1	2.13×10^5	3.22×10^{-3}	0.12	0.01	1.00
413D2	8.20	2.75×10^5	2.26×10^{-3}	0.15	0.02	0.99
393C5	2.44	4.75×10^5	1.16×10^{-3}	0.15	0.01	1.00
388D4	2.69	3.71×10^5	9.99×10^{-4}	0.16	0.01	1.00
413E1	58.9	5.07×10^5	2.99×10^{-2}	0.12	0.01	0.99

G. Selectivity of anti-PD-1 antibodies

[0160] To assess selectivity of the anti-PD-1 antibodies, ELISA was used to generate dose response curves for binding of the anti-PD-1 antibodies to several immunomodulatory cell surface proteins. Recombinant soluble extracellular domains (ECDs) of ICOS (inducible T-cell costimulator), PD-1, CD28 or CTLA4 (R&D Systems, Minneapolis, MN) were coated onto ELISA assay plates. Binding of each anti-PD-1 antibody and each control antibody to each target protein was then assessed over a range of antibody concentrations (FIGS. 9A-9D).

[0161] These experiments demonstrated that anti-PD-1 antibodies 388D4, 413E1, 244C8 and 246A10 bind to the PD-1 ECD with high specificity, showing no binding to three structurally related Ig-superfamily protein members

EXAMPLE 3. Humanization of Anti-PD-1 Antibodies

[0162] Humanization of selected anti-PD-1 antibodies was performed in order to reduce the apparent immunogenicity of the mouse-based antibodies. Using antibody engineering information well known in the art, and conventional bioinformatics tools, amino acid sequences of certain murine anti-PD-1 antibodies of the invention were analyzed and compared against known human antibody sequences. Based on these analyses and comparisons, certain human sequences

EP 3 916 017 A1

were chosen for conventional murine CDR grafting, and inclusion of suitable back mutations. In tests for binding to human PD-1, these humanized antibodies were evaluated with respect to criteria such as affinity, avidity, binding kinetics, and biochemical behavior such as aggregation as well as expression levels. The HCVR and LCVR amino acid sequences of certain humanized antibodies displaying desirable characteristics (e.g., binding to PD-1) are shown in Tables 7 and 8, respectively. FIGS. 10A and 10B show amino acid sequence alignments of the humanized heavy or light chain variable region sequences with the indicated murine heavy (100388_D4_VH3 or 100244_C8_VH3) or light chain (100389_D4_VK5 or 100245_C8_Vk5m1) variable region sequences.

Table 7. Humanized heavy chain variable region sequences

HCVR designation	Amino Acid Sequence	SEQ ID NO:
100244_C8_HC1	QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYWMHWVRQAPGQGLEWMGMIDPSNSETS LNQKFQGRVTMTVDKSTNTVYMELSSLRSE DTAVYYCARSRGNYAYEMDYWGQGLTVV SS	85
100244_C8_HC2	EVQLVQSGAEVKKPGASVKVSCKASGYTFTS YWMHWVRQAPGQGLEWMGMIDPSNSETSL NQKFQGRVTLNVDKSTNTAYMELSSLRSEDT AVYYCARSRGNYAYEMDYWGQGLTVVSS	86
100244_C8_HC3	EVQLVQSGTEVTKPGASVKVSCKASGYTFTS YWMHWVRQAPGQGLEWLG MIDPSNSETTL NQKFQGRVTMTVDKSTNTVYMELTSLRSED TAVYYCARSRGNYAYEMDYWGQGLTVVS S	87
100388_D4_HC1	EVQLVQSGAEVKKPGASVKVSCKASGYTFT DYEMHWVRQAPGQGLEWMGIIDPGTGGTA YNQKFQGRVTMTADKSTSTVYMELSSLRSE DTAVYYCTSEKFGSNYYFDYWGQGLTVVS S	88
100388_D4_HC2	EVQLVQSGAEVKKPGASVKVSCKASGYTFT DYEMHWVRQAPGQGLEWMGIIDPGTGGTA YNQKFQGRVTMTADKSTNTVYMELSSLRSE DTAVYYCTSEKFGSNYYFDYWGQGLTVVS S	89
100388_D4_HC3	EVQLVQSGAEVKKPGASVKVSCKASGYTFT DYEMHWVRQAPGQRLEWMGVIDPGTGGTA YNQKFQGRVTITADKSASTAYMELSSLRSED TAVYYCTSEKFGSNYYFDYWGQGLTVVSS	90

EP 3 916 017 A1

Table 8. Humanized light chain variable region sequences

LCVR designation	minoAcid Sequence	SEQ ID NO:
100245_C8_LC1	EIVLTQSPATLSLSPGERATLSCRASSSVSSN YLYWYQQKPGQAPRLLIYSTSNRATGIPARF SGSGSGTDYTLTISSLEPEDFAVYYCHQWSS YPPTFGQGTKLEIK	91
100245_C8_LC2	DIVLTQSPATLSLSPGERATLSCRASSSVSSN YLYWYQQKPGQAPRLLIYSTSNLATGIPARF SGSGSGTDYTLTISSLEPEDFAVYFCHQWSS YPPTFGQGTKLEIK	92
100245_C8_LC3	DIVLTQSPGTLSPGKVTLSRASSSVSSN YLYWYQQKPGQAPRLVIYSTSNLATGIPDRF SGSGSGTDYTLTISRLEPEDFAVYFCHQWSS YPPTFGQGTKVEIK	93
100389_D4_LC1	DVVMTQSPLSLPVTLGQPASISCRSSQTIVHS DGNTYLEWYQQRPGQSPRLLIYKVSNRFSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYC FQGSHVPLTFGQGTKLEIK	94
100389_D4_LC2	DIVMTQSPLSLPVTLGQPASISCRSSQTIVHS DGNTYLEWYQQRPGQSPKLLIYKVSNRFSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYC FQGSHVPLTFGQGTKLEIK	95
100389_D4_LC3	DIVMTQTPLSSPVTLGQPASISCRSSQTIVHS DGNTYLEWYQQRPGQPPRLLIYKVSNRFSG VPDRFSGSGAGTDFTLKISRVEAEDVGVYY CFQGSHVPLTFGQGTKLEIK	96

Table 9. HCVR and LCVR pairings for humanized antibodies

Humanized Antibody Designation	Heavy Chain Variable Region	Light Chain Variable Region
244C8-1	100244_C8_HC1 (SEQ ID NO: 85)	100245_C8_LC1 (SEQ ID NO: 91)
244C8-2	100244_C8_HC1 (SEQ ID NO: 85)	100245_C8_LC3 (SEQ ID NO: 93)
244C8-3	100244_C8_HC2 (SEQ ID NO: 86)	100245_C8_LC1 (SEQ ID NO: 91)
388D4-1	100388_D4_HC3 (SEQ ID NO: 90)	100389_D4_LC1 (SEQ ID NO: 94)
388D4-2	100388_D4_HC3 (SEQ ID NO: 90)	100389_D4_LC3 (SEQ ID NO: 96)
388D4-3	100388_D4_HC1 (SEQ ID NO: 88)	100389_D4_LC3 (SEQ ID NO: 96)

EXAMPLE 4. Antibody-Ligand Competition for Binding to PD-1

A. Competitive Binding Assays

[0163] It was found that while some of the anti-PD-1 antibodies disclosed herein competitively inhibit binding of PD-1 ligands, others do not. For example, in surface plasmon resonance-based competitive binding assays and flow cytometry-based competitive binding assays, it was found that antibody 388D4 competitively inhibits binding of PD-L1 to

EP 3 916 017 A1

PD-1, but does not inhibit binding of PD-L2. In contrast, it was found that antibody 244C8 does not competitively inhibit binding of PD-L1 or PD-L2.

[0164] Competitive Binding Analysis was performed on humanized IgG₄ antibodies 244C8-2 and 388D4-2, using ForteBio Biolayer Interferometry (BLI). Humanized IgG antibody was immobilized to AHC biosensors by loading 3 μg/mL IgG to a target level of 1.0 nm over a 160 second load time. A single concentration (100 nM) of active PD-1, plus an appropriate negative control to correct for drift, was bound the immobilized IgG. A pH of 7.4 was used for association and dissociation. The bound PD-1 was then exposed to seven concentrations of PD-L1 (9, 3, 1, 0.333, 0.111, 0.037, and 0 μM) or PD-L2 (2000, 666.7, 222.2, 74.1, 24.7, 8.2, and 0 nM). The association/dissociation of PD-L1 and PD-L2 to the mAb/PD-1 complex immobilized on biosensor tips was evaluated.

[0165] Materials used in these assays were as follows: PD1 (His Tag): ABCAM, Cat# ab174035, Lot# GR199119-1, 100 mg; PD-L1 (His Tag): Sino Biological, Cat# 10084-H08H, Lot# LC098E0901, 200 mg; PD-L2 (His Tag): Sino Biological, Cat# 10292-H08H, Lot# LC07DE3022, 100 mg; PD1-Fc: R&D Systems, Cat# 1086-PD, Lot# FVQ0413051, 50 mg; Anti-Human IgG-Fc Capture (AHC) Biosensors: ForteBio, Cat# 18-5060, Lot# 1501211; IX Kinetic Buffer: 20 mM Phosphate, 150 mM NaCl, 0.02 % Tween-20, 0.05% Sodium Azide, 0.1 mg/ml BSA, pH 7.4; Test Samples: Humanized IgG₄ - 244C8-2 (3.04 mg/mL), Humanized IgG₄ - 388D4-2 (2.89 mg/mL).

[0166] The flow cytometry assays were conducted essentially as follows. HEK293 cells expressing PD-1 were incubated with 10 μg/ml of an isotype antibody (negative control), commercially available antibody EH12.2H7 (positive control), antibody 388D4, or antibody 244C8. Cells were washed and stained with soluble PD-L1-Ig protein fluorescently labeled with Alexa-488. Cells were washed again, and PD-L1 binding (by displacing previously bound antibody) was assessed by fluorescence activated cell sorting (FACS) analysis. Representative results are shown in FIGS. 11A-11D.

EXAMPLE 5. Human Cell Based Assays

A. Human Cells

[0167] Human tumor tissue procurement and tumor dissociation were as follows. Fresh tumor samples from NSCLC patients undergoing surgical resection of tumors were obtained from the Cooperative Human Tissue Network, National Cancer Institute. Analysis was performed using single-cell suspensions of tumor cells from these tumor samples.

[0168] Solid tumor biopsy samples were mechanically disrupted into single-cell suspensions using a gentleMACS Dissociator (Miltenyi Biotec) with enzymes A, H and R. The single-cell suspensions were then prepared for cell counting and initial FACS analysis.

B. FACS Analysis

[0169] For FACS analysis, anti-CD45-PerCP-Cy5.5 (clone 2D1), anti-CD4-PE-Cy7 (SK3), anti-CD8-FITC (SKI), anti-BTLA-Biotin (MIH26), anti-CTLA-4-PE (14D3), and anti-LAG-3-APC (3DS223H) were purchased from eBioscience. Anti-CD25-BV605 (2A3), anti-PD-1-BV605 (EH121), and Streptavidin-BV711 were purchased from BD Bioscience. Anti-CD45RABV421 (HI100), anti-CCR7 AlexaFluor647 (G043H7), and anti-Tim-3-BV421 (F38-2E2) were purchased from Biolegend. Heterogeneous cell suspensions prepared from dissociated primary tumors (as described above) were washed, resuspended in PBS, and blocked with a commercial Fc blocking reagent (BD Biosciences). Viable cells were identified by lack of dead cell staining positivity, and by negativity for EpCAM expression. CD45-positive cells were gated for CD4 or CD8 expression, and then the cells were assessed for expression of PD-1, TIM3, LAG3 or TIGIT. These FACS data are shown below, in Table 10, with results expressed as percentage of positive cells.

Table 10. Results of FACS analysis

Tumor	% Ep- CAM- CD45+	%CD3+	%CD4+PD1+	%CD8+PD1+	%CD4+TIM3+	%CD8+TIM3+	%CD4+LAG3+	%CD8+LAG3+	%CD4+TIGIT+	%CD8+TIGIT+
WD-36444	25.7	14	55	75	5.5	13	<1	<1	6	6.3
WD-36571	10.3	6.3	47	64	1.8	<1%	0	0	12.6	21
WD-36686	21.6	17	55	84	6	16	0	0	20	15
WD-36790	16.8	10.4	38	68	1	5.2	<1	<1	33	47
WD-36904	12.8	7	63	72	9.5	24.5	<1	<1	41	25.6
M115801A2	3.4	2.9	79	84	22	16	1.4	1.6	56	35
WD-36923	1.6	0.9	53	51	27				24.5	
WD-36988	8.9	7	58	93	22	62	0	0	25	52
M4150952	5.4	3	78	79	26	15	0	0	32	23

[0170] The T cell surface marker expression data in Table 10 provide a comparison of the immunomodulatory receptor profiles of tumor infiltrating lymphocytes (TILs) from various human NSCLC tumor biopsy samples. Such data provided a useful biological context for the assays performed using the tumor samples.

5 C. Stimulation of Tumor infiltrating lymphocytes (TILs)

[0171] To establish polyclonal stimulation of TILs among the dissociated tumor cells, a 96-well assay plate was coated with 0.5 $\mu\text{g/mL}$ anti-CD3 (OKT3) in coupling buffer, overnight at 4°C. The antibody coating solution was removed, and the plate was washed. Tumor suspensions were resuspended to a density of approximately 1.5×10^6 cells per mL. Then 200 μL of this was added to each experimental well, together with 2 $\mu\text{g/mL}$ anti-CD28 (clone 28.2, eBioscience). At specific time points, supernatants were used for ELISA analysis or cells were used for FACS analysis or single cell analysis on microwell array devices.

15 D. Enzyme-linked immunosorbent assay

[0172] Supernatants from cultured tumor digests containing tumor cells, stromal cells and immune cells were collected at fixed time points after experimental treatment, and cytokine production was assessed by ELISA. To begin the ELISA, 96-well plates were coated with capture antibody, blocked with assay diluent buffer, and washed, prior to incubation with serial dilutions of supernatants from the cultured tumor-derived cells. The samples were incubated for one hour, and then the ELISA plates were washed. The detection antibody-HRP, in assay diluent, was then added, the assay plate was washed, and substrate solution was added to the wells in the assay plate. After the enzyme reaction was stopped, colorimetric density at 450 nm was measured in a conventional plate reader. Measurements of $\text{IFN}\gamma$ secretion, normalized to internal standards included on each plate, was used as the experimental readout for T cell effector function.

25 E. TIL Function Increased by PD-1 Blockade

[0173] FIG. 12 summarizes results from an experiment showing restoration of T cell function by PD-1 blockade with nivolumab or different humanized forms of antibodies 388D4 and 244C8, *i.e.*, 388D4-2, 388D4-3, 244C8-1, 244C8-2, and 244C8-3. A population of 3×10^5 cells, which included 17% lymphocytes (activated as described above) was incubated for 24 hours with anti-PD-1 antibodies at a concentration of 20 $\mu\text{g/mL}$. $\text{IFN}\gamma$ was measured by ELISA, and the data were expressed in terms of fold-activation relative to treatment with the isotype control antibody. As shown in FIG. 12, each of the anti-PD-1 antibodies restored T cell function, increasing $\text{IFN}\gamma$ secretion approximately 7- to 8-fold, relative to the isotype control. The data illustrated in FIG. 12 are presented in Table 11 below.

35 Table 11. Restoration of T cell function by PD-1 blockade

	Fold Induction $\text{IFN}\gamma$	Standard Deviation
Isotype Control	1.00	0.39
nivolumab	7.07	0.15
388D4-2	7.58	0.23
388D4-3	7.20	0.23
244C8-1	8.04	0.33
244C8-2	7.76	0.11
244C8-3	7.79	0.42

[0174] FIG. 13 summarizes results from an experiment to measure the increase in T cell effector function, as indicated by $\text{IFN}\gamma$ secretion, in response to treatment with antibody 244C8-2 alone versus treatment with 244C8-2 plus 388D4-2, with results normalized relative to the response to treatment with nivolumab. A population of 3×10^5 cells, which included 7.5% lymphocytes sub-optimally activated as described above, was incubated for 24 hours with anti-PD-1 antibodies at a total antibody concentration of 20 $\mu\text{g/mL}$. As shown in FIG. 13, treatment with 244C8-2 alone increased $\text{IFN}\gamma$ 1.77-fold (± 0.19 sd), while treatment with 244C8-2 in combination with 388D4-2 increased $\text{IFN}\gamma$ secretion 2.11-fold (± 0.21 sd). These unexpected results obtained in response to treatment with the combination of a competitive inhibitory antibody and a non-competitive inhibitory antibody indicate that combining these two different mechanisms of action to inhibit PD-1 produces an enhanced response, despite the fact that both antibodies are directed against the same target. The data illustrated in FIG. 13 are presented in Table 12 below.

Table 12. Increase in IFN- γ induction by combination of anti-PD-1 antibodies

	Fold Induction IFN- γ	Standard Deviation
Nivolumab	1.00	0.12
244C8-2	1.77	0.19
388D4-2 + 244C8-2	2.11	0.21

[0175] FIG. 14 shows results from an experiment similar to the experiment yielding the results presented in FIG. 12, except that different humanized forms of antibodies 388D4 and 244C8 were tested, and nivolumab was tested in combination with 244C8. In each treatment, a population of 3×10^5 cells, which included 9% lymphocytes (sub-optimally activated as described above) was incubated for 24 hours with anti-PD-1 antibodies at a total concentration of 20 $\mu\text{g}/\text{mL}$. Following PD-1 blockade, cells and supernatants were collected for FACS analysis, analysis by microengraving in a microwell array device (Varadarajan, supra), or ELISA detection of cytokines. FIG. 14 shows IFN γ secretion, as measured by ELISA, with data expressed in terms of fold-induction of IFN γ secretion, relative to treatment with the isotype control antibody. The data used to create FIG. 14 are shown in Table 13 below.

Table 13. Increase in IFN- γ induction by combination of anti-PD-1 antibodies

	Fold Induction IFN- γ	Standard Deviation
anti-CD3+anti-CD28 only	1.00	0.25
Nivolumab (10 $\mu\text{g}/\text{mL}$)	1.89	0.07
388D4-2 (5 $\mu\text{g}/\text{mL}$)	2.06	0.12
388D4-2 (10 $\mu\text{g}/\text{mL}$)	1.82	0.38
244C8-2 (5 $\mu\text{g}/\text{mL}$)	2.66	0.49
244C8-2 (10 $\mu\text{g}/\text{mL}$)	2.81	0.42
388D4-2 (5 $\mu\text{g}/\text{mL}$)+244C8-2 (5 $\mu\text{g}/\text{mL}$)	2.85	0.55
Nivolumab (5 $\mu\text{g}/\text{mL}$)+244C8-2 (5 $\mu\text{g}/\text{mL}$)	3.76	0.08

[0176] The data summarized in FIG. 14 show significantly increased response to treatment of TILs from NSCLC biopsies with the combination of nivolumab, which is a competitive inhibitory anti-PD-1 antibody, and 244C8-2, which is a non-competitive inhibitory anti-PD-1 antibody. Individual antibody treatment with each of two different anti-PD-1 antibodies that compete with PD-L1 for binding to PD-L1, *i.e.*, nivolumab and 388D4-2, increased T cell effector function approximately 2-fold. Individual antibody treatment with an anti-PD-1 antibody that does not compete with PD-L1 for binding to PD-L1, *i.e.*, 244C8-2, increased T cell effector function between 2.5-fold and 3-fold. Treatment with nivolumab plus 244C8-2 increased T cell effector function between 3.5-fold and 4-fold.

[0177] When experiments such as these are performed on human patient tumor biopsy samples, the magnitude of increase in T cell effector function observed in response to the same antibody treatment can vary from experiment to experiment as a function of patient-to-patient variation. In spite of such patient-to-patient variation, these results indicate that the addition of a non-competitive inhibitory anti-PD-1 antibody treatment to a competitive inhibitory anti-PD-1 antibody treatment can yield a greater increase in effector function of TILs, as compared to treatment with the competitive inhibitory anti-PD-1 antibody alone.

F. Antibody 244C8 and Cytokine Secretion in MLR Assays

[0178] Increased secretion of various cytokines was observed in response to antibody 244C8 in mixed lymphocyte reaction (MLR) assays. FIGS. 15A-15F summarize the results of an MLR assay performed on human PBMCs treated with anti-PD-1 antibodies. The MLR assay was performed using commercially available monocyte-derived dendritic cells as stimulator cells and purified CD4 $^+$ T lymphocytes as responder cells from a different healthy blood donor. Supernatants were collected at 2.5 days after beginning the assay. Cytokine secretion was measured in a multiplex capture sandwich immunoassay using MagPlex $^{\text{®}}$ microspheres (Luminex, Austin, TX) and ProCartaPlex $^{\text{®}}$ Human TH1/TH2 Chemokine Panel (Luminex), according to the vendor's instructions. Fluorescence of the various labels was detected using a MagPix $^{\text{®}}$ fluorescence detection system (Luminex). The data in FIGS. 15A-15F indicate that treatment with antibody 244C8-1

resulted in increased secretion of cytokines IL-6, IL-12, IL-18, TNF- α , GM-CSF, and IL-1 β , in comparison with antibody 388D4-2 or the IgG4 isotype control (Biolegend). Similar results (data not shown) were observed with cells from two other blood donors, at two time points.

5 G. Antibody 244C8 and Cytokine Secretion by TILs

[0179] Increased secretion of various cytokines by TILs was observed in response to antibody 244C8. FIGS. 16A-16F show alteration of tumor infiltrating lymphocyte (TIL) function by PD-1 blockade with antibodies 388D4-2, and 244C8-2. In this experiment, a population of 3×10^5 dissociated and suspended human cells from a non-small cell lung cancer (NSCLC) biopsy, which included 7% lymphocytes that had been activated as described in Example 5C (above) was incubated for 24 hours with an anti-PD-1 antibody or IgG4 isotype control, at a concentration of 10 μ g/mL. Cytokine secretion was measured in a multiplex capture sandwich immunoassay using MagPlex[®] microspheres (Luminex) and ProCartaPlex[®] Human TH1/TH2 Chemokine Panel (Luminex), according to the vendor's instructions. Fluorescence of the various labels was detected using a MagPix[®] fluorescence detection system (Luminex). These data indicate that treatment with antibody 244C8-2 resulted in increased secretion of cytokines IL-6, IL-12, IL-18, TNF- α , GM-CSF, and IL-1 β , in comparison with antibody 388D4-2 or the IgG4 isotype control (Biolegend). Similar results (not shown) were obtained by employing this protocol with three other human tumor samples.

EXAMPLE 6. Animal Models

20

A. Patient-Derived Xenografts in Humanized Mice

[0180] Antibodies 244C8 and 388D4 displayed anti-tumor activity in patient-derived xenograft (PDX) tumor growth in humanized mice. FIG. 17A shows results from an in vivo efficacy experiment involving a human lung tumor PDX-derived from a metastatic stage IV non-small cell lung cancer (NSCLC) patient (lung tumor LG1306; Jackson Labs) implanted in mice engineered to have a human immune system (hu-CD34 NSG[™] mice; Jackson Labs). The five treatment groups were: vehicle control, antibody 388D4-3, antibody 244C8-2, pembrolizumab, or a combination of antibody 244C8-2 and pembrolizumab. Mice that had been engrafted with human CD34+ cells and had >25% human CD45+ cells in the peripheral blood at twelve weeks post-engraftment were implanted subcutaneously on the right flank with tumor fragments from PDX model LG1306. Mice were randomized into five treatment groups (n=10), based on tumor volume, when volume reached 60-120 mm³. Animals received a total of six intra-peritoneal 5 mg/kg doses at five-day intervals (Q5D x 6). All doses were delivered in PBS as vehicle. In the treatment groups that received 388D4-3, 244C8-2, or pembrolizumab, the first dose of the antibody was given as a 10 mg/kg dose, followed by the additional doses at the 5 mg/kg dose. The combination treatment group (244C8-2 + pembrolizumab) received a dose each of 5 mg/kg pembrolizumab and 5 mg/kg of 244C8-2 at each dosing time point. Tumor volumes were measured twice weekly (Day 3, 6, 10, 13, 17, 20, 24 and 28) using a digital caliper to determine length and width of the tumors. Error bars represent the 95% confidence interval.

[0181] All treatment groups showed significant tumor growth inhibition compared to the vehicle control group. In this experiment, no significant difference in tumor growth inhibition was observed among treatment with antibody 388D4-3, antibody 244C8-2, pembrolizumab, or the combination of antibody 244C8-2 with pembrolizumab. As shown in FIG. 17B, at day 28 (end of study), the tumor volume for each of the treatment groups was significantly smaller than the vehicle group. The Student T-test p values between each treatment group and the vehicle group were: pembrolizumab = 0.00167; 388D4 = 0.00105; 244C8 = 0.00277; and pembrolizumab and 244C8 in combination = 0.00275. FIG. 17C shows percentage tumor volume of each treatment group relative to vehicle on day 28. The calculated percent tumor growth inhibition (%TGI) for each treatment is shown above each bar in FIG. 17C. Percent tumor growth inhibition was calculated according to the following formula:

$$\% \text{ TGI on Day X} = (1 - (T_{\text{DayX}} - T_{\text{Day-1}}) / (C_{\text{DayX}} - C_{\text{Day-1}})) * 100$$

50

where:

T = the average tumor volume for a treatment group; and

C = the average tumor volume for the control group.

55

[0182] In this experiment, it was surprisingly discovered that in the combination treatment, a combined antibody dose totaling 10mg/kg was well tolerated by the animals, for the duration of the study.

INCORPORATION BY REFERENCE

[0183] The relevant teachings of all patents, published applications, and references cited herein are incorporated by reference in their entirety.

EQUIVALENTS

[0184] While this invention has been particularly shown and described with references to examples of embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

[0185] The following numbered clauses, describing aspects of the invention, are part of the description.

1. An isolated antibody that binds to programmed cell death protein 1 (PD-1), comprising a heavy chain variable region (HCVR) having complementarity determining regions (CDRs) selected from the group consisting of: CDRs 1-3 of SEQ ID NO: 1; CDRs 1-3 of SEQ ID NO: 2; CDRs 1-3 of SEQ ID NO: 3; CDRs 1-3 of SEQ ID NO: 4; CDRs 1-3 of SEQ ID NO: 5; CDRs 1-3 of SEQ ID NO: 6; CDRs 1-3 of SEQ ID NO: 7; CDRs 1-3 of SEQ ID NO: 8; CDRs 1-3 of SEQ ID NO: 9; CDRs 1-3 of SEQ ID NO: 10; CDRs 1-3 of SEQ ID NO: 11; CDRs 1-3 of SEQ ID NO: 12; CDRs 1-3 of SEQ ID NO: 13; CDRs 1-3 of SEQ ID NO: 14; CDRs 1-3 of SEQ ID NO: 15; CDRs 1-3 of SEQ ID NO: 16; CDRs 1-3 of SEQ ID NO: 17; CDRs 1-3 of SEQ ID NO: 18; CDRs 1-3 of SEQ ID NO: 19; CDRs 1-3 of SEQ ID NO: 20; CDRs 1-3 of SEQ ID NO: 21; CDRs 1-3 of SEQ ID NO: 22; CDRs 1-3 of SEQ ID NO: 23; CDRs 1-3 of SEQ ID NO: 24; CDRs 1-3 of SEQ ID NO: 25; and CDRs 1-3 of SEQ ID NO: 26.

2. An isolated antibody that binds to PD-1, comprising a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 1-26.

3. An isolated antibody that binds to PD-1, comprising a light chain variable region (LCVR) having CDRs selected from the group consisting of: CDRs 1-3 of SEQ ID NO: 27; CDRs 1-3 of SEQ ID NO: 28; CDRs 1-3 of SEQ ID NO: 29; CDRs 1-3 of SEQ ID NO: 30; CDRs 1-3 of SEQ ID NO: 31; CDRs 1-3 of SEQ ID NO: 32; CDRs 1-3 of SEQ ID NO: 33; CDRs 1-3 of SEQ ID NO: 34; CDRs 1-3 of SEQ ID NO: 35; CDRs 1-3 of SEQ ID NO: 36; CDRs 1-3 of SEQ ID NO: 37; CDRs 1-3 of SEQ ID NO: 38; CDRs 1-3 of SEQ ID NO: 39; CDRs 1-3 of SEQ ID NO: 40; CDRs 1-3 of SEQ ID NO: 41; CDRs 1-3 of SEQ ID NO: 42; CDRs 1-3 of SEQ ID NO: 43; CDRs 1-3 of SEQ ID NO: 44; CDRs 1-3 of SEQ ID NO: 45; CDRs 1-3 of SEQ ID NO: 46; CDRs 1-3 of SEQ ID NO: 47; CDRs 1-3 of SEQ ID NO: 48; CDRs 1-3 of SEQ ID NO: 49; CDRs 1-3 of SEQ ID NO: 50; CDRs 1-3 of SEQ ID NO: 51; CDRs 1-3 of SEQ ID NO: 52; and CDRs 1-3 of SEQ ID NO: 53.

4. An isolated antibody that binds to PD-1, comprising a LCVR selected from the group consisting of SEQ ID NOs: 27-53.

5. An isolated antibody that binds to PD-1, comprising a HCVR selected from the group consisting of SEQ ID NOs: 1-26 and a LCVR selected from the group consisting of SEQ ID NOs: 27-53.

6. The antibody according to any one of Clause 1-5, wherein the antibody comprises a HCVR and LCVR pair selected from the group consisting of: a HCVR having the sequence set forth in SEQ ID NO: 4 and a LCVR having the sequence set forth in SEQ ID NO: 28 (244C7); a HCVR having the sequence set forth in SEQ ID NO: 4 and a LCVR having the sequence set forth in SEQ ID NO: 27 (244C7ml); a HCVR having the sequence set forth in SEQ ID NO: 1 and a LCVR having the sequence set forth in SEQ ID NO: 28 (244C8); a HCVR having the sequence set forth in SEQ ID NO: 1 and a LCVR having the sequence set forth in SEQ ID NO: 27 (244C8ml); a HCVR having the sequence set forth in SEQ ID NO: 3 and a LCVR having the sequence set forth in SEQ ID NO: 31 (246F7); a HCVR having the sequence set forth in SEQ ID NO: 5 and a LCVR having the sequence set forth in SEQ ID NO: 44 (258C1); a HCVR having the sequence set forth in SEQ ID NO: 2 and a LCVR having the sequence set forth in SEQ ID NO: 30 (258F6); a HCVR having the sequence set forth in SEQ ID NO: 2 and a LCVR having the sequence set forth in SEQ ID NO: 29 (258F6m); a HCVR having the sequence set forth in SEQ ID NO: 6 and a LCVR having the sequence set forth in SEQ ID NO: 34 (392C4); a HCVR having the sequence set forth in SEQ ID NO: 7 and a LCVR having the sequence set forth in SEQ ID NO: 41 (394D5); a HCVR having the sequence set forth in SEQ ID NO: 8 and a LCVR having the sequence set forth in SEQ ID NO: 35 (394G1); a HCVR having the sequence set forth in SEQ ID NO: 12 and a LCVR having the sequence set forth in SEQ ID NO: 39 (388C12A); a HCVR having the sequence set forth in SEQ ID NO: 12 and a LCVR having the sequence set forth in SEQ ID NO: 32 (388C12B); a HCVR having the sequence set forth in SEQ ID NO: 13 and a LCVR having the sequence set forth in SEQ ID NO: 39 (388C16A);

EP 3 916 017 A1

a HCVR having the sequence set forth in SEQ ID NO: 13 and a LCVR having the sequence set forth in SEQ ID NO: 32 (388C16B); a HCVR having the sequence set forth in SEQ ID NO: 9 and a LCVR having the sequence set forth in SEQ ID NO: 38 (392C5A); a HCVR having the sequence set forth in SEQ ID NO: 9 and a LCVR having the sequence set forth in SEQ ID NO: 37 (392C5B); a HCVR having the sequence set forth in SEQ ID NO: 17 and a LCVR having the sequence set forth in SEQ ID NO: 40 (392D2); a HCVR having the sequence set forth in SEQ ID NO: 16 and a LCVR having the sequence set forth in SEQ ID NO: 43 (392H4); a HCVR having the sequence set forth in SEQ ID NO: 20 and a LCVR having the sequence set forth in SEQ ID NO: 53 (246A10); a HCVR having the sequence set forth in SEQ ID NO: 18 and a LCVR having the sequence set forth in SEQ ID NO: 47 (388D4); a HCVR having the sequence set forth in SEQ ID NO: 19 and a LCVR having the sequence set forth in SEQ ID NO: 48 (392A6); a HCVR having the sequence set forth in SEQ ID NO: 21 and a LCVR having the sequence set forth in SEQ ID NO: 52 (411C2); a HCVR having the sequence set forth in SEQ ID NO: 22 and a LCVR having the sequence set forth in SEQ ID NO: 51 (413D2); and a HCVR having the sequence set forth in SEQ ID NO: 25 and a LCVR having the sequence set forth in SEQ ID NO: 45 (413E1).

7. The antibody according to any one of Clause 1-6, comprising a HCVR having the sequence set forth in SEQ ID NO: 20 and a LCVR having the sequence set forth in SEQ ID NO: 53 (246A10); a HCVR having the sequence set forth in SEQ ID NO: 25 and a LCVR having the sequence set forth in SEQ ID NO: 45 (413E1); a HCVR having the sequence set forth in SEQ ID NO: 22 and a LCVR having the sequence set forth in SEQ ID NO: 51 (413D2); a HCVR having the sequence set forth in SEQ ID NO: 18 and a LCVR having the sequence set forth in SEQ ID NO: 47 (388D4); a HCVR having the sequence set forth in SEQ ID NO: 1 and a LCVR having the sequence set forth in SEQ ID NO: 28 (244C8); or a HCVR having the sequence set forth in SEQ ID NO: 9 and a LCVR having the sequence set forth in SEQ ID NO: 38 (392C5A).

8. The antibody according to Clause 1 or 3 comprising a humanized or human framework region.

9. An isolated antibody that binds to PD-1, comprising a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 85-90.

10. An isolated antibody that binds to PD-1, comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NOs: 91-96.

11. An isolated antibody that binds to PD-1, comprising a HCVR selected from the group consisting of SEQ ID NOs: 85-90 and a LCVR selected from the group consisting of SEQ ID NOs: 91-96.

12. The antibody according to any one of Clause 9-11, comprising a HCVR having the sequence set forth in SEQ ID NO: 90 and a LCVR having the sequence set forth in SEQ ID NO: 94; a HCVR having the sequence set forth in SEQ ID NO: 88 and a LCVR having the sequence set forth in SEQ ID NO: 96; a HCVR having the sequence set forth in SEQ ID NO: 90 and a LCVR having the sequence set forth in SEQ ID NO: 96; a HCVR having the sequence set forth in SEQ ID NO: 85 and a LCVR having the sequence set forth in SEQ ID NO: 91; a HCVR having the sequence set forth in SEQ ID NO: 85 and a LCVR having the sequence set forth in SEQ ID NO: 93; or a HCVR having the sequence set forth in SEQ ID NO: 86 and a LCVR having the sequence set forth in SEQ ID NO: 91.

13. An isolated antibody that binds to PD-1, wherein the antibody binds to a sequence in PD-1 selected from the group consisting of SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, and SEQ ID NO: 84.

14. The antibody according to any one of Clause 1-13, wherein the antibody is monoclonal.

15. The antibody according to any one of Clause 1-14, wherein the antibody is a PD-1 agonist.

16. The antibody according to any one of Clause 1-14, wherein the antibody is a PD-1 antagonist.

17. An isolated antibody that binds to PD-1 and competitively inhibits the binding of the antibody according to any one of Clause 1-16 to human PD-1.

18. The antibody of Clause 17, wherein said antibody binds to a sequence in PD-1 selected from the group consisting of SEQ ID NOs: 54-84.

19. The antibody of Clause 17, wherein said antibody competitively inhibits the binding of an antibody of Clause 6.

20. An isolated nucleic acid comprising a nucleotide sequence encoding the HCVR of Clause 1 or 9.

21. An expression vector comprising the nucleic acid of Clause 20.

22. A host cell transformed with an expression vector of Clause 21.

23. An isolated nucleic acid comprising a nucleotide sequence encoding the LCVR of Clause 3 or 10.

24. An expression vector comprising the nucleic acid of Clause 23.

25. A host cell transformed with an expression vector of Clause 24.

26. A method of producing an antibody comprising a HCVR, a LCVR, or a combination thereof, the method comprising:

- (a) growing the host cell of Clause 22 or 25, under conditions such that the host cell expresses the antibody comprising the HCVR, the LCVR, or a combination thereof; and
- (b) isolating the antibody comprising the HCVR, the LCVR, or combination thereof.

27. A method of treating a PD-1-mediated disease or disorder in a mammal, comprising administering an effective amount of the antibody according to any one of Clause 1-19 to a mammal in need thereof.

28. The method of Clause 27, wherein the mammal has an immune disorder or cancer.

29. A method of diagnosing a PD-1-mediated adaptive immune resistance in a patient who has cancer, comprising:

- contacting a tumor microenvironment in the patient with the antibody according to any one of Clause 1-19 labeled with a detectable moiety; and detecting expression of PD-1 on CD8+ T cells within the tumor microenvironment.

30. The method of Clause 29, further comprising detecting expression of PD-L1 in the tumor microenvironment.

31. A method for increasing T cell effector function, comprising contacting a T cell with a combination of: (a) an effective amount of an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell; and (b) an effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell.

32. The method of Clause 31, wherein the T cell is contacted with the combination *in vivo*.

33. The method of Clause 32, wherein the T cell is contacted with the combination in a human patient in need of increased T cell effector function.

34. A method of treating cancer in a mammal, comprising contacting a T cell in a mammal in need thereof with a combination of: (a) an effective amount of an anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell; and (b) an effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell.

35. The method of Clause 34, wherein the cancer is selected from the group consisting of:

- melanoma, renal cancer, prostate cancer, pancreatic adenocarcinoma, breast cancer, colon cancer, lung cancer, esophageal cancer, squamous cell carcinoma of the head and neck, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, and lymphoma.

36. The method of Clause 31 or 34, wherein the anti-PD-1 antibody that competitively inhibits binding of PD-L1 or

EP 3 916 017 A1

PD-L2 to PD-1 expressed on the surface of a T cell is selected from the group consisting of: 388D4, nivolumab, pembrolizumab, EH12.2H7 and J105.

5 37. The method of Clause 36, wherein the anti-PD-1 antibody that competitively inhibits binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell is 388D4.

38. The method of Clause 1 or 4, wherein the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell is 244C8.

10 39. The method of Clause 31 or 34, wherein the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell binds to one or more of the following amino acid sequences: SEQ ID NO: 74, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 83 and SEQ ID NO: 84.

15 40. The method of Clause 39, wherein the anti-PD-1 antibody binds to all of the following amino acid sequences: SEQ ID NO: 74, SEQ ID NO: 77, SEQ ID NO: 80, SEQ ID NO: 83 and SEQ ID NO: 84.

41. The method of Clause 31 or 34, wherein the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell binds to a PD-1 epitope bound by 244C8.

20 42. The method of Clause 31 or 34, wherein the anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell competes with 244C8 for binding to PD-1.

25 43. A method for increasing T cell effector function, comprising contacting a T cell with an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of the T cell.

30 44. A method for increasing lymphocyte secretion of a cytokine selected from the group consisting of IL-6, IL-12, IL-18, TNF- α , IL-1 β and GM-CSF in a human patient in need of increased T cell effector function, comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antibody that does not competitively inhibit binding of PD-L1 or PD-L2 to PD-1 expressed on the surface of a T cell.

35 45. The method of Clause 43 or 44, wherein the antibody comprises a heavy chain variable region having complementarity determining regions (CDRs) selected from the group consisting of CDRs 1-3 of SEQ ID NO:85, CDRs 1-3 of SEQ ID NO:86, and CDRs 1-3 of SEQ ID NO:87; and a light chain variable region having CDRs selected from the group consisting of CDRs 1-3 of SEQ ID NO:91, CDRs 1-3 of SEQ ID NO:92, and CDRs 1-3 of SEQ ID NO:93.

46. The method of Clause 45, wherein the antibody comprises a heavy chain variable region selected from the group consisting of SEQ ID NOS: 85, 86 and 87 and a light chain variable region selected from the group consisting of SEQ ID NOS: 91, 92 and 93.

40 47. The method of Clause 45 or 46, wherein the antibody is selected from the group consisting of antibody 244C8-1, antibody 244C8-2 and antibody 244C8-3.

45

50

55

EP 3 916 017 A1

SEQUENCE LISTING

<110> Enumeral Biomedical Holdings, Inc.

5

<120> Anti-PD-1 Antibodies

<130> 007912322

10

<140> EP

<141> 2015-12-19

<150> EP15821000.5

<151> 2015-12-19

15

<150> PCT/US2015/066954

<151> 2015-12-19

<150> US 62/095,675

<151> 2014-12-22

20

<150> US 62/220,199

<151> 2015-09-17

<150> us 62/251,082

<151> 2015-11-04

25

<150> US 62/261,118

<151> 2015-11-30

<160> 97

30

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 120

<212> PRT

<213> Mus musculus

35

<400> 1

Glu	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Trp	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
		35					40					45			
Gly	Met	Ile	Asp	Pro	Ser	Asn	Ser	Glu	Thr	Ser	Leu	Asn	Gln	Lys	Phe
	50					55					60				
Lys	Asp	Lys	Ala	Thr	Leu	Asn	Val	Asp	Lys	Ser	Thr	Asn	Thr	Ala	Tyr
	65				70					75					80
Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Ser	Arg	Gly	Asn	Tyr	Ala	Tyr	Glu	Met	Asp	Tyr	Trp	Gly	Gln
			100					105						110	
Gly	Thr	Ser	Val	Thr	Val	Ser	Ser								
		115					120								

50

<210> 2

<211> 120

<212> PRT

55

EP 3 916 017 A1

<213> Mus musculus

<400> 2

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

Glu	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Trp	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
		35					40					45			
Gly	Met	Ile	Glu	Pro	Ser	Ser	Ser	Glu	Thr	Ser	Leu	Asn	Gln	Lys	Phe
	50					55					60				
Lys	Asp	Lys	Ala	Thr	Leu	Asn	Val	Asp	Lys	Ser	Ser	Asn	Thr	Ala	Tyr
65					70					75					80
Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Ser	Arg	Gly	Asn	Tyr	Ala	Tyr	Glu	Met	Asp	Tyr	Trp	Gly	Gln
			100					105					110		
Gly	Thr	Ser	Val	Thr	Val	Ser	Ser								
		115					120								

<210> 3

<211> 120

<212> PRT

<213> Mus musculus

<400> 3

25
 30
 35
 40
 45
 50
 55

Glu	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Trp	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
		35					40					45			
Gly	Met	Ile	Asp	Pro	Tyr	Ser	Ser	Glu	Thr	Ser	Leu	Asn	Gln	Lys	Phe
	50					55					60				
Lys	Asp	Lys	Ala	Thr	Leu	Asn	Val	Asp	Lys	Ile	Ser	Asn	Thr	Ala	Tyr
65					70					75					80
Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Phe	Cys
				85					90					95	
Ala	Arg	Ser	Arg	Gly	Asn	Tyr	Ala	Tyr	Asp	Met	Asp	Tyr	Trp	Gly	Gln
			100					105					110		
Gly	Thr	Ser	Val	Thr	Val	Ser	Ser								
		115					120								

<210> 4

<211> 120

<212> PRT

<213> Mus musculus

<400> 4

45
 50
 55

Glu	Val	Gln	Leu	Gln	Glu	Ser	Gly	Pro	Glu	Leu	Val	Arg	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
			20					25					30		
Trp	Met	His	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
		35					40					45			
Gly	Met	Ile	Asp	Pro	Ser	Asn	Ser	Glu	Thr	Ser	Leu	Asn	Gln	Lys	Phe
	50					55					60				
Lys	Asp	Lys	Ala	Thr	Leu	Asn	Val	Asp	Lys	Ser	Ser	Lys	Thr	Ala	Tyr
65					70					75					80
Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
				85					90					95	

EP 3 916 017 A1

Ala Arg Ser Arg Gly Asn Tyr Ala Tyr Asp Met Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Ser Val Thr Val Ser Ser
 115 120

5

<210> 5
 <211> 117
 <212> PRT
 <213> Mus musculus

10

<400> 5
 Glu Val Gln Leu Gln Glu Ser Gly Ala Glu Leu Val Met Pro Gly Ala
 1 5 10 15
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 Gly Ala Ile Asp Thr Ser Asp Ser Tyr Thr Ser Tyr His Gln Asn Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Glu Asp Glu Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys
 85 90 95
 Ala Arg Arg Asp Tyr Gly Gly Phe Gly Tyr Trp Gly Gln Gly Thr Thr
 100 105 110
 Leu Thr Val Ser Ser
 115

15

20

25

<210> 6
 <211> 116
 <212> PRT
 <213> Mus musculus

30

<400> 6
 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Asn Met Asp Trp Val Lys Lys Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Asp Ile Asp Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Trp Arg Ser Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
 100 105 110
 Thr Val Ser Ser
 115

35

40

45

<210> 7
 <211> 116
 <212> PRT
 <213> Mus musculus

50

<400> 7
 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Pro Cys Arg Ala Ser Gly Tyr Ile Phe Thr Asp Tyr

55

EP 3 916 017 A1

<210> 10
 <211> 116
 <212> PRT
 <213> Mus musculus

5

<400> 10
 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Thr Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 10 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Asp Ile Asp Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr
 65 70 75 80
 15 Met Glu Leu Arg Ser Leu Ala Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Trp Arg Ser Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
 100 105 110
 Ser Val Ser Ser
 20 115

<210> 11
 <211> 116
 <212> PRT
 <213> Mus musculus

25

<400> 11
 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 30 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Asp Ile Asp Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Asn Phe
 50 55 60
 35 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Trp Arg Ser Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
 100 105 110
 40 Thr Val Ser Ser
 115

<210> 12
 <211> 116
 <212> PRT
 <213> Mus musculus

45

<400> 12
 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 50 Gly Asp Ile Asp Pro Asn Asn Gly Gly Ile Ile Tyr Asn Gln Lys Phe
 55 55 60
 Lys Gly Lys Ala Ala Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr

EP 3 916 017 A1

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Arg Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Asn Met Asp Trp Val Met Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Asp Ile Asp Pro Asn Asn Gly Gly Thr Ile Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Trp Arg Ser Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 16
 <211> 116
 <212> PRT
 <213> Mus musculus

20
 25
 30
 35
 40
 45
 50
 55

<400> 16
 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Asn Val Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Asp Ile Asp Pro Asn Asn Gly Gly Thr Phe Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala His
 65 70 75 80
 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Val Arg Trp Arg Ser Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 17
 <211> 116
 <212> PRT
 <213> Mus musculus

45
 50
 55

<400> 17
 Glu Val Gln Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Asp Ile Asp Pro Asn Thr Gly Thr Thr Phe Tyr Asn Gln Asp Phe
 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Trp Arg Ser Ser Met Asp Tyr Trp Gly Gln Gly Thr Ser Leu
 100 105 110
 Thr Val Ser Ser

115

5
 <210> 18
 <211> 120
 <212> PRT
 <213> Mus musculus

10
 <400> 18
 Glu Val Gln Leu Gln Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
 1 5 10 15
 Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Met His Trp Val Lys Gln Thr Pro Val His Gly Leu Glu Trp Ile
 35 40 45
 15 Gly Val Ile Asp Pro Gly Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
 50 55 60
 Lys Val Lys Ala Leu Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 20 Thr Ser Glu Lys Phe Gly Ser Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Thr Leu Thr Val Ser Ser
 115 120

25
 <210> 19
 <211> 120
 <212> PRT
 <213> Mus musculus

30
 <400> 19
 Glu Val Gln Leu Gln Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
 1 5 10 15
 Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Ile His Trp Val Lys Gln Thr Pro Val His Gly Leu Glu Trp Ile
 35 40 45
 Gly Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
 50 55 60
 Lys Gly Lys Ala Ile Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 40 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95
 Thr Ser Glu Lys Phe Gly Ser Ser Tyr Tyr Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Thr Phe Thr Val Ser Ser
 115 120

45
 <210> 20
 <211> 118
 <212> PRT
 <213> Mus musculus

50
 <400> 20
 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
 20 25 30
 Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
 35 40 45

55

EP 3 916 017 A1

Met Gly Tyr Ile Thr Tyr Ser Gly Ser Pro Thr Tyr Asn Pro Ser Leu
 50 55 60
 Lys Ser Gln Phe Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
 65 70 75 80
 5 Leu Gln Leu Asn Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Leu Gly Gly His Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 Thr Leu Thr Val Ser Ser
 115

<210> 21
 <211> 118
 <212> PRT
 <213> Mus musculus

<400> 21
 Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
 20 20 25 30
 Tyr Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
 35 40 45
 Met Gly Tyr Ile Thr Tyr Ser Gly Ser Pro Thr Tyr Asn Pro Ser Leu
 50 55 60
 25 Lys Ser Gln Phe Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
 65 70 75 80
 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Leu Gly Gly His Tyr Phe Asp Tyr Trp Gly Gln Gly Thr
 100 105 110
 30 Thr Leu Thr Val Ser Ser
 115

<210> 22
 <211> 117
 <212> PRT
 <213> Mus musculus

<400> 22
 Glu Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Gly
 20 25 30
 Tyr Ser Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu Glu Trp
 35 40 45
 Met Gly Phe Ile His Tyr Ser Gly Asp Thr Asn Tyr Asn Pro Ser Leu
 50 55 60
 45 Lys Ser Arg Phe Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe Phe
 65 70 75 80
 Leu His Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Thr Tyr Tyr Cys
 85 90 95
 50 Ala Ser Pro Ser Arg Leu Leu Phe Asp Tyr Trp Gly His Gly Thr Thr
 100 105 110
 Leu Thr Val Ser Ser
 115

<210> 23
 <211> 113
 <212> PRT

EP 3 916 017 A1

<213> Mus musculus

<400> 23

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
 20 25 30
 Gly Val Asp Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
 35 40 45
 Gly Val Ile Trp Gly Val Gly Ser Thr Asn Tyr Asn Ser Ala Leu Lys
 50 55 60
 Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
 65 70 75 80
 Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala
 85 90 95
 Ser Asp Gly Phe Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
 100 105 110
 Ser

<210> 24

<211> 113

<212> PRT

<213> Mus musculus

<400> 24

25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105
 110

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
 20 25 30
 Gly Val Asp Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
 35 40 45
 Gly Val Ile Trp Gly Ile Gly Ser Thr Asn Tyr Asn Ser Ala Leu Lys
 50 55 60
 Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
 65 70 75 80
 Lys Met Asn Ser Leu Gln Ser Asp Asp Thr Ala Met Tyr Tyr Cys Ala
 85 90 95
 Ser Asp Gly Phe Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
 100 105 110
 Ser

<210> 25

<211> 114

<212> PRT

<213> Mus musculus

<400> 25

45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95

Glu Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
 20 25 30
 Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
 35 40 45
 Gly Val Ile Trp Arg Gly Gly Asn Thr Asp Tyr Asn Ala Ala Phe Met
 50 55 60
 Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
 65 70 75 80
 Lys Met Asn Ser Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
 85 90 95

EP 3 916 017 A1

Ala Ser Met Ile Gly Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val
 100 105 110
 Ser Ser

5

<210> 26
 <211> 114
 <212> PRT
 <213> Mus musculus

10

<400> 26
 Glu Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Gln Pro Ser Gln
 1 5 10 15
 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Asn Tyr
 20 25 30
 Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu
 35 40 45
 Gly Val Ile Trp Arg Gly Gly Asn Thr Asp Tyr Asn Ala Ala Phe Met
 50 55 60
 Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Phe
 65 70 75 80
 Lys Phe His Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala
 85 90 95
 Ala Ser Met Ile Gly Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val
 100 105 110
 Ser Ser

15

20

25

<210> 27
 <211> 108
 <212> PRT
 <213> Mus musculus

30

<400> 27
 Asp Ile Val Leu Thr Gln Thr Pro Ala Ile Met Ser Ala Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Asn
 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Lys Leu Trp
 35 40 45
 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
 65 70 75 80
 Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105

35

40

45

<210> 28
 <211> 108
 <212> PRT
 <213> Mus musculus

50

<400> 28
 Asp Ile Val Ile Thr Gln Thr Thr Ala Ile Met Ser Ala Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Asn
 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Lys Leu Trp

55

EP 3 916 017 A1

35 40 45
 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
 50 55 60
 5 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
 65 70 75 80
 Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105

10
 <210> 29
 <211> 108
 <212> PRT
 <213> Mus musculus

15
 <400> 29
 Asp Ile Val Met Thr Gln Thr Pro Ala Thr Met Ser Ala Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asn Ser Asn
 20 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Val Trp
 35 40 45
 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
 50 55 60
 25 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
 65 70 75 80
 Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys
 100 105

30
 <210> 30
 <211> 108
 <212> PRT
 <213> Mus musculus

35
 <400> 30
 Asp Ile Val Met Thr Gln Thr Thr Ala Thr Met Ser Ala Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Asn Ser Asn
 40 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Val Trp
 35 40 45
 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
 50 55 60
 45 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu
 65 70 75 80
 Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys
 100 105

50
 <210> 31
 <211> 108
 <212> PRT
 <213> Mus musculus

55
 <400> 31
 Asp Ile Val Leu Thr Gln Ser Thr Ala Ile Met Ser Ala Ser Pro Gly
 1 5 10 15

EP 3 916 017 A1

5
 10
 15
 20
 25
 30

Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Gly Val Asn Ser Asn
 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp
 35 40 45
 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu
 65 70 75 80
 Ala Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 32
 <211> 107
 <212> PRT
 <213> Mus musculus

20
 25
 30

<400> 32
 Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 33
 <211> 107
 <212> PRT
 <213> Mus musculus

40
 45
 50

<400> 33
 Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 34
 <211> 107
 <212> PRT
 <213> Mus musculus

EP 3 916 017 A1

<400> 34

Asp Ile Val Ile Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Glu Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 35

<211> 107

<212> PRT

<213> Mus musculus

<400> 35

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Arg Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Asn Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 36

<211> 107

<212> PRT

<213> Mus musculus

<400> 36

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Glu Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 37

<211> 107

EP 3 916 017 A1

<212> PRT
 <213> Mus musculus

<400> 37

5 Asp Ile Val Met Thr Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser His Tyr
 20 25 30
 10 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Arg Asn Leu Glu Pro
 65 70 75 80
 15 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Glu Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 38
 <211> 107
 <212> PRT
 <213> Mus musculus

<400> 38

25 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser His Tyr
 20 25 30
 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Arg Asn Leu Glu Pro
 65 70 75 80
 35 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Glu Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 39
 <211> 107
 <212> PRT
 <213> Mus musculus

<400> 39

45 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Asp Ile Ser Ser Tyr
 20 25 30
 50 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 55 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Glu Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

EP 3 916 017 A1

<210> 40
 <211> 107
 <212> PRT
 <213> Mus musculus

5

<400> 40
 Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Tyr Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Ile Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Leu Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Glu Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

10

15

20

<210> 41
 <211> 107
 <212> PRT
 <213> Mus musculus

25

<400> 41
 Asp Ile Val Met Thr Gln Thr Pro Ser Ser Met Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Tyr Leu Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

30

35

40

<210> 42
 <211> 107
 <212> PRT
 <213> Mus musculus

45

<400> 42
 Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Gly Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Thr Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Arg Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Asn Leu Pro Trp
 85 90 95

50

55

EP 3 916 017 A1

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

5
 <210> 43
 <211> 107
 <212> PRT
 <213> Mus musculus

10
 <400> 43
 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 15 35 40 45
 Tyr Tyr Thr Ser Asn Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asp Leu Ala Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Tyr Leu Pro Trp
 20 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

25
 <210> 44
 <211> 112
 <212> PRT
 <213> Mus musculus

30
 <400> 44
 Asp Ile Val Ile Thr Gln Ser Pro Leu Ser Leu Pro Val Gly Leu Gly
 1 5 10 15
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
 20 25 30
 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 35 40 45
 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser
 85 90 95
 Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 40 100 105 110

45
 <210> 45
 <211> 112
 <212> PRT
 <213> Mus musculus

50
 <400> 45
 Asp Ile Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
 1 5 10 15
 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser
 20 25 30
 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 35 40 45
 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asn Phe Thr Leu Lys Ile

EP 3 916 017 A1

Pro Asn Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 5 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95
 Ser His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 100 105 110

10 <210> 49
 <211> 112
 <212> PRT
 <213> Mus musculus

15 <400> 49
 Asp Ile Val Leu Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly
 1 5 10 15
 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
 20 25 30
 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
 20 35 40 45
 Pro Gln Val Leu Ile Tyr Phe Met Ser Thr Arg Ala Ser Gly Val Ser
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile
 65 70 75 80
 25 Ser Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
 85 90 95
 Val Asp Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Leu Lys
 100 105 110

30 <210> 50
 <211> 112
 <212> PRT
 <213> Mus musculus

35 <400> 50
 Asp Ile Val Met Thr Gln Asp Glu Leu Tyr Asn Pro Val Thr Ser Gly
 1 5 10 15
 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
 20 25 30
 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
 40 35 40 45
 Pro Gln Val Leu Ile Tyr Phe Met Ser Thr Arg Ala Ser Gly Val Ser
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile
 65 70 75 80
 45 Ser Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
 85 90 95
 Val Asp Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

50 <210> 51
 <211> 113
 <212> PRT
 <213> Mus musculus

55 <400> 51
 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
 1 5 10 15
 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser

EP 3 916 017 A1

<220>
<223> PD-1 peptide sequence

5 <400> 54
Met Gln Ile Pro Gln Ala Pro Trp Pro Val Val Trp Ala Val Leu
1 5 10 15

10 <210> 55
<211> 15
<212> PRT
<213> Artificial Sequence

15 <220>
<223> PD-1 peptide sequence

<400> 55
Ala Pro Trp Pro Val Val Trp Ala Val Leu Gln Leu Gly Trp Arg
1 5 10 15

20 <210> 56
<211> 15
<212> PRT
<213> Artificial Sequence

25 <220>
<223> PD-1 peptide sequence

30 <400> 56
Val Trp Ala Val Leu Gln Leu Gly Trp Arg Pro Gly Trp Phe Leu
1 5 10 15

35 <210> 57
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> PD-1 peptide sequence

40 <400> 57
Gln Leu Gly Trp Arg Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg
1 5 10 15

45 <210> 58
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> PD-1 peptide sequence

50 <400> 58
Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro
1 5 10 15

55 <210> 59
<211> 15

EP 3 916 017 A1

<212> PRT
<213> Artificial Sequence

<220>
<223> PD-1 peptide sequence

<400> 59
Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr Phe Ser Pro Ala
1 5 10 15

<210> 60
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> PD-1 peptide sequence

<400> 60
Pro Trp Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val Val Thr
1 5 10 15

<210> 61
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> PD-1 peptide sequence

<400> 61
Thr Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp Asn Ala
1 5 10 15

<210> 62
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> PD-1 peptide sequence

<400> 62
Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe Thr Cys Ser
1 5 10 15

<210> 63
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> PD-1 peptide sequence

<400> 63
Glu Gly Asp Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser
1 5 10 15

EP 3 916 017 A1

<210> 64
 <211> 15
 <212> PRT
 <213> Artificial Sequence

5

<220>
 <223> PD-1 peptide sequence

<400> 64
 Thr Phe Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val Leu
 1 5 10 15

10

<210> 65
 <211> 15
 <212> PRT
 <213> Artificial Sequence

15

<220>
 <223> PD-1 peptide sequence

<400> 65
 Phe Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Met
 1 5 10 15

20

<210> 66
 <211> 15
 <212> PRT
 <213> Artificial Sequence

25

<220>
 <223> PD-1 peptide sequence

30

<400> 66
 Glu Ser Phe Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln
 1 5 10 15

35

<210> 67
 <211> 15
 <212> PRT
 <213> Artificial Sequence

40

<220>
 <223> PD-1 peptide sequence

<400> 67
 Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala
 1 5 10 15

45

<210> 68
 <211> 15
 <212> PRT
 <213> Artificial Sequence

50

<220>
 <223> PD-1 peptide sequence

<400> 68
 Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp
 1 5 10 15

55

EP 3 916 017 A1

<210> 69
<211> 15
<212> PRT
<213> Artificial Sequence

5

<220>
<223> PD-1 peptide sequence

<400> 69
Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly
1 5 10 15

10

<210> 70
<211> 15
<212> PRT
<213> Artificial Sequence

15

<220>
<223> PD-1 peptide sequence

20

<400> 70
Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe
1 5 10 15

25

<210> 71
<211> 15
<212> PRT
<213> Artificial Sequence

30

<220>
<223> PD-1 peptide sequence

<400> 71
Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu
1 5 10 15

35

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence

40

<220>
<223> PD-1 peptide sequence

<400> 72
Gln Asp Cys Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg Asp
1 5 10 15

45

<210> 73
<211> 15
<212> PRT
<213> Artificial Sequence

50

<220>
<223> PD-1 peptide sequence

55

<400> 73

EP 3 916 017 A1

Arg Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His Met Ser Val
 1 5 10 15

5 <210> 74
 <211> 15
 <212> PRT
 <213> Artificial Sequence

10 <220>
 <223> PD-1 peptide sequence

<400> 74
 Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg Ala Arg Arg
 1 5 10 15

15 <210> 75
 <211> 15
 <212> PRT
 <213> Artificial Sequence

20 <220>
 <223> PD-1 peptide sequence

25 <400> 75
 Phe His Met Ser Val Val Arg Ala Arg Arg Asn Asp Ser Gly Thr
 1 5 10 15

30 <210> 76
 <211> 15
 <212> PRT
 <213> Artificial Sequence

35 <220>
 <223> PD-1 peptide sequence

<400> 76
 Val Arg Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala
 1 5 10 15

40 <210> 77
 <211> 15
 <212> PRT
 <213> Artificial Sequence

45 <220>
 <223> PD-1 peptide sequence

<400> 77
 Asn Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro
 1 5 10 15

50 <210> 78
 <211> 15
 <212> PRT
 <213> Artificial Sequence

55 <220>
 <223> PD-1 peptide sequence

EP 3 916 017 A1

<400> 78

Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys
 1 5 10 15

5

<210> 79

<211> 15

<212> PRT

<213> Artificial Sequence

10

<220>

<223> PD-1 peptide sequence

<400> 79

Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala
 1 5 10 15

15

<210> 80

<211> 15

<212> PRT

<213> Artificial Sequence

20

<220>

<223> PD-1 peptide sequence

25

<400> 80

Lys Ala Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val Thr
 1 5 10 15

30

<210> 81

<211> 15

<212> PRT

<213> Artificial Sequence

35

<220>

<223> PD-1 peptide sequence

<400> 81

Glu Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu
 1 5 10 15

40

<210> 82

<211> 15

<212> PRT

<213> Artificial Sequence

45

<220>

<223> PD-1 peptide sequence

<400> 82

Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His
 1 5 10 15

50

<210> 83

<211> 15

<212> PRT

<213> Artificial Sequence

55

EP 3 916 017 A1

<220>
<223> PD-1 peptide sequence

5 <400> 83
Glu Arg Arg Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro
1 5 10 15

10 <210> 84
<211> 16
<212> PRT
<213> Artificial Sequence

15 <220>
<223> PD-1 peptide sequence

<400> 84
Val Pro Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe
1 5 10 15

20 <210> 85
<211> 120
<212> PRT
<213> Artificial Sequence

25 <220>
<223> humanized-heavy chain variable region

<400> 85
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
30 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 35 40 45
Gly Met Ile Asp Pro Ser Asn Ser Glu Thr Ser Leu Asn Gln Lys Phe
50 55 60
35 Gln Gly Arg Val Thr Met Thr Val Asp Lys Ser Thr Asn Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
40 Ala Arg Ser Arg Gly Asn Tyr Ala Tyr Glu Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120

45 <210> 86
<211> 120
<212> PRT
<213> Artificial Sequence

50 <220>
<223> humanized-heavy chain variable region

<400> 86
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
55 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

EP 3 916 017 A1

5
10
15
20
25
30
35
40
45
50
55

Gly Met Ile Asp Pro Ser Asn Ser Glu Thr Ser Leu Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Leu Asn Val Asp Lys Ser Thr Asn Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Gly Asn Tyr Ala Tyr Glu Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 87
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> humanized-heavy chain variable region

<400> 87
1 5 10 15
Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Thr Lys Pro Gly Ala
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu
35 40 45
Gly Met Ile Asp Pro Ser Asn Ser Glu Thr Thr Leu Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Val Asp Lys Ser Thr Asn Thr Val Tyr
65 70 75 80
Met Glu Leu Thr Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Ser Arg Gly Asn Tyr Ala Tyr Glu Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 88
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> humanized-heavy chain variable region

<400> 88
1 5 10 15
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Asp Pro Gly Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Thr Ser Glu Lys Phe Gly Ser Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Leu Val Thr Val Ser Ser

EP 3 916 017 A1

115

120

5

<210> 89
 <211> 120
 <212> PRT
 <213> Artificial Sequence

10

<220>
 <223> humanized-heavy chain variable region

15

<400> 89
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
 35 40 45
 Gly Ile Ile Asp Pro Gly Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Met Thr Ala Asp Lys Ser Thr Asn Thr Val Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Ser Glu Lys Phe Gly Ser Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 115 120

20

25

30

<210> 90
 <211> 120
 <212> PRT
 <213> Artificial Sequence

35

<220>
 <223> humanized-heavy chain variable region

40

<400> 90
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met
 35 40 45
 Gly Val Ile Asp Pro Gly Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe
 50 55 60
 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Ala Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Ser Glu Lys Phe Gly Ser Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 115 120

50

55

<210> 91
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>

EP 3 916 017 A1

<223> humanized-light chain variable region

<400> 91

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Ser Asn
 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Ser Thr Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 92

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> humanized-light chain variable region

<400> 92

25
 30
 35
 40
 45
 50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Ser Asn
 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Ser Thr Ser Asn Leu Ala Thr Gly Ile Pro Ala Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 93

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> humanized-light chain variable region

<400> 93

50
 55
 60
 65
 70
 75
 80
 85
 90
 95
 100
 105

Asp Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Lys Val Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Ser Asn
 20 25 30
 Tyr Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Val
 35 40 45
 Ile Tyr Ser Thr Ser Asn Leu Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80

EP 3 916 017 A1

Pro Glu Asp Phe Ala Val Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro
 85 90 95
 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

5

<210> 94
 <211> 112
 <212> PRT
 <213> Artificial Sequence

10

<220>
 <223> humanized-light chain variable region

<400> 94
 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Ile Val His Ser
 20 25 30
 Asp Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95
 Ser His Val Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105 110

15

20

25

<210> 95
 <211> 112
 <212> PRT
 <213> Artificial Sequence

30

<220>
 <223> humanized-light chain variable region

<400> 95
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Ile Val His Ser
 20 25 30
 Asp Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser
 35 40 45
 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95
 Ser His Val Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 100 105 110

35

40

45

<210> 96
 <211> 112
 <212> PRT
 <213> Artificial Sequence

50

<220>
 <223> humanized-light chain variable region

55

<400> 96

Asp Ile Val Met Thr Gln Thr Pro Leu Ser Ser Pro Val Thr Leu Gly
 1 5 10 15
 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Thr Ile Val His Ser
 5 20 25 30
 Asp Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Pro
 35 40 45
 Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60
 Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile
 10 65 70 75 80
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
 85 90 95
 Ser His Val Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 15 100 105 110

<210> 97

<211> 143

<212> PRT

<213> Homo sapiens

<400> 97

Pro Asp Arg Pro Trp Asn Pro Pro Thr Phe Ser Pro Ala Leu Leu Val
 1 5 10 15
 Val Thr Glu Gly Asp Asn Ala Thr Phe Thr Cys Ser Phe Ser Asn Thr
 25 20 25 30
 Ser Glu Ser Phe Val Leu Asn Trp Tyr Arg Met Ser Pro Ser Asn Gln
 35 35 40 45
 Thr Asp Lys Leu Ala Ala Phe Pro Glu Asp Arg Ser Gln Pro Gly Gln
 50 55 60
 Asp Cys Arg Phe Arg Val Thr Gln Leu Pro Asn Gly Arg Asp Phe His
 65 70 75 80
 Met Ser Val Val Arg Ala Arg Arg Asn Asp Ser Gly Thr Tyr Leu Cys
 85 90 95
 Gly Ala Ile Ser Leu Ala Pro Lys Ala Gln Ile Lys Glu Ser Leu Arg
 35 100 105 110
 Ala Glu Leu Arg Val Thr Glu Arg Arg Ala Glu Val Pro Thr Ala His
 115 120 125
 Pro Ser Pro Ser Pro Arg Pro Ala Gly Gln Phe Gln Thr Val Val
 40 130 135 140

Claims

1. An isolated antibody that binds to programmed cell death protein 1 (PD-1), comprising:

a heavy chain variable region (HCVR) comprising the sequence set forth in SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the sequence set forth in SEQ ID NO: 28 (244C8);
 a HCVR comprising the sequence set forth in SEQ ID NO: 85 and a LCVR comprising the sequence set forth in SEQ ID NO: 91 (244C8-1);
 a HCVR comprising the sequence set forth in SEQ ID NO: 85 and a LCVR comprising the sequence set forth in SEQ ID NO: 93 (244C8-2); or
 a HCVR comprising the sequence set forth in SEQ ID NO: 86 and a LCVR comprising the sequence set forth in SEQ ID NO: 91 (244C8-3).

2. The antibody according to claim 1, comprising a HCVR comprising the sequence set forth in SEQ ID NO: 85 and a LCVR comprising the sequence set forth in SEQ ID NO: 91 (244C8-1).

3. The antibody according to claim 1, comprising a HCVR comprising the sequence set forth in SEQ ID NO: 85 and a

EP 3 916 017 A1

LCVR comprising the sequence set forth in SEQ ID NO: 93 (244C8-2).

4. The antibody according to claim 1, comprising or a HCVR comprising the sequence set forth in SEQ ID NO: 86 and a LCVR comprising the sequence set forth in SEQ ID NO: 91 (244C8-3).

5

5. The antibody according to any one of claims 1-4, wherein the antibody is monoclonal.

6. The antibody according to any one of claims 1-4, wherein the antibody is a PD-1 antagonist.

10

7. The antibody according to any one of the preceding claims for use in a method of treating a cancer in a mammal comprising administering an effective amount of the antibody to a mammal in need thereof.

8. The antibody for use of claim 7, wherein the cancer is lung cancer.

15

9. An in vitro method of diagnosing an adaptive immune resistance in a patient who has cancer, comprising:

contacting a tumor microenvironment in a biopsy sample from the patient with the antibody according to any one of claims 1 to 6, labeled with a detectable moiety; and
detecting expression of PD-1 on CD8+ T cells within the tumor microenvironment.

20

10. The method of claim 9, further comprising detecting expression of PD-L1 in the tumor microenvironment.

25

30

35

40

45

50

55

100244	C8_VH3	EVQLOESGPE	LVRPGASVVM	SCRKASGYTFF	--SYWHRVVKQ	RFGQGLEWIG	MIDPENSETS	LNOKFKDKAT
100258	F6_VH4	EVQLOESGPK	LVRPGASVVM	SCRKASGYTFF	--SYWHRVVKQ	RFGQGLEWIG	MIDPENSETS	LNOKFKDKAT
100246	F7_VH3	EVQLOESGPE	LVRPGASVVM	SCRKASGYTFF	--SYWHRVVKQ	RFGQGLEWIG	MIDPENSETS	LNOKFKDKAT
100244	C7_VH10	EVQLOESGPE	LVRPGASVVM	SCRKASGYTFF	--SYWHRVVKQ	RFGQGLEWIG	MIDPENSETS	LNOKFKDKAT
100258	C1_VH4	EVQLOESGAE	LVRPGASVVM	SCRKASGYTFF	--DYWHRVVKQ	RFGQGLEWIG	AIDTSESYTS	YHONFKGKAT
100394	G1_VH1	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100392	C4_VH5	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100394	D5_VH9	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100392	C5_VH6	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100394	F1_VH8	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100388	C1_VH3	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100388	C1_VH6	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100388	G1_VH5	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100392	H4_VH9	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100392	D2_VH7	EVQLOESGPE	LVRPGASVKI	PCRKASGYTFF	--DYNMDVVKQ	SHGKSLKMWG	DIDPNSGGTI	YHONFKGKAT
100388	D4_VH3	EVQLOESGPE	LVRPGASVTL	SCRKASGYTFF	--DYEMHWVKQ	TPVHGLEWIG	VIDPNTGTTA	YHONFKVVKAL
100392	A6_VH8	EVQLOESGAE	LVRPGASVTL	SCRKASGYTFF	--DYEIERVVKQ	TPVHGLEWIG	AIDPNTGTTA	YHONFKVVKAL
100411	C2_VH3	EVQLOESGPG	LVRPQSLSL	TCTVSGYSIT	SDYAWRWIRO	FPGNKLEWNG	YITY--SGSPT	YHONFKVVKAL
100411	A10_VH1	EVQLOESGPG	LVRPQSLSL	TCTVSGYSIT	SDYAWRWIRO	FPGNKLEWNG	YITY--SGSPT	YHONFKVVKAL
100413	D2_VH9	EVQLOESGPG	LVRPQSLSL	TCTVSGYSIT	SGYAWRWIRO	FPGNKLEWNG	FVHY--SGSPT	YHONFKVVKAL
100388	H4_VH1	EVQLOESGPG	LVRPQSLSL	TCTVSGYSIT	--RFEVDVVKQ	SPGKLEWIG	VWMS--VGSPT	YHONFKVVKAL
100392	C3_VH7	EVQLOESGPG	LVRPQSLSL	TCTVSGYSIT	--SYGVVDVVKQ	SPGKLEWIG	VWMS--VGSPT	YHONFKVVKAL
100413	E1_VH9	EVQLOESGPE	LVRPQSLSL	TCTVSGYSIT	--SYGVVDVVKQ	SPGKLEWIG	VWMS--VGSPT	YHONFKVVKAL
100413	H1_VH3	EVQLOESGPE	LVRPQSLSL	TCTVSGYSIT	--NYGVHWVKQ	SPGKLEWIG	VWMS--VGSPT	YHONFKVVKAL
100244	C8_VH3	LVVDKSSNTA	YMLRSLTSE	DSAVYYCARR	RGNYAYEMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100258	F6_VH4	LVVDKSSNTA	YMLRSLTSE	DSAVYYCARR	RGNYAYEMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100246	F7_VH3	LVVDKSSNTA	YMLRSLTSE	DSAVYYCARR	RGNYAYEMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100244	C7_VH10	LVVDKSSNTA	YMLRSLTSE	DSAVYYCARR	RGNYAYEMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100258	C1_VH4	LVVDKSSSTA	YMLRSLTSE	DSAVYYCARR	DY-----GGFGY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100394	G1_VH1	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100392	C4_VH5	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100394	D5_VH9	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100392	C5_VH6	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100392	H3_VH6	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100394	F1_VH8	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100388	C1_VH3	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100388	C1_VH6	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100388	G1_VH5	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100392	H4_VH9	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100392	D2_VH7	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100398	D4_VH3	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100392	A6_VH8	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100411	C2_VH3	LVVDKSSSTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100411	C2_VH9	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100413	D2_VH9	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100388	H4_VH1	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100392	C3_VH7	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100413	E1_VH9	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS
100413	H1_VH3	LVVDKSSNTA	YMLRSLTSE	DTAVYYCARR	R-----SSMDY	WQOQTSVTVS	WQOQTSVTVS	WQOQTSVTVS




FIG. 1

100245...C8...Vk5m1	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100245...C8...Vk5	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100259...F6...VK1m1	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100259...F6...VK1	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100247...F7...VK2	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100389...C1...VK2	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100395...F1...VK4	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100395...F1...VK4	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100395...C4...VK8	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100395...C1...VK4	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100389...G1...VK1	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100393...C5...VK10	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100389...C5...VK7	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100389...C1...VK1	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100393...D2...VK5	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100395...D5...VK7	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100393...H3...VK2	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100393...B4...VK10/H4...VK6	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100259...C1...VK1	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100414...E1...VK5	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100414...H1...VK6	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100389...D4...VK5	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100393...A6...VK5	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100389...H4...VK4	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100393...C3...VK10	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100414...D2...VK6	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100412...C2...VK7	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100247...A10...VK3	DIVLTQYPAI	MSASFGGERVT	LTCSSASSSV	...SSNYLY	WYQORFGSSP	KLWLYSTSNL
100245...C8...Vk5m1	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100245...C8...Vk5	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100259...F6...VK1m1	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100259...F6...VK1	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100247...F7...VK2	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100389...C1...VK2	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100395...F1...VK4	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100395...F1...VK4	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100393...C4...VK8	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100395...C1...VK4	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100389...G1...VK1	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100393...C5...VK10	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100393...C5...VK7	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100395...D5...VK7	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100393...H3...VK2	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100393...B4...VK10/H4...VK6	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100259...C1...VK1	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100414...E1...VK5	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100414...H1...VK6	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100389...D4...VK5	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100393...A6...VK5	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100389...H4...VK4	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100393...C3...VK10	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100414...D2...VK6	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100412...C2...VK7	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK
100247...A10...VK3	ASGVPAKFSQ	SGSGTFSYSLT	LSMEAKDAA	SYFCHOWSSY	PPTFGSGTKL	EIK

FIG. 2



FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B

246A10
PDRPWNPTTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPEDRSQPQDCRFRVTQLPNGRDFHFM
SVVRRRNDSGTYLCCGAISSLAPKAQIKESLRAELRVTERRAEVPTAHPSPRPAGQFQT (SEQ ID NO: 97)

244C8
PDRPWNPTTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPEDRSQPQDCRFRVTQLPNGRDFHFM
SVVRRRNDSGTYLCCGAISSLAPKAQIKESLRAELRVTERRAEVPTAHPSPRPAGQFQT (SEQ ID NO: 97)

388D4
PDRPWNPTTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPEDRSQPQDCRFRVTQLPNGRDF
HMSVVRARRNDSGTYLCCGAISSLAPKAQIKESLRAELRVTERRAEVPTAHPSPRPAGQFQT (SEQ ID NO: 97)

413D2
PDRPWNPTTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPEDRSQPQDCRFRVTQLPNGRDF
HMSVVRARRNDSGTYLCCGAISSLAPKAQIKESLRAELRVTERRAEVPTAHPSPRPAGQFQT (SEQ ID NO: 97)

413E1
PDRPWNPTTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAPEDRSQPQDCRFRVTQLPNGRDFHFM
SVVRRRNDSGTYLCCGAISSLAPKAQIKESLRAELRVTERRAEVPTAHPSPRPAGQFQT (SEQ ID NO: 97)

FIG. 8

FIG. 9A




FIG. 9B




FIG. 9C





FIG. 9D






FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 12




FIG. 13




FIG. 14




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 15E




FIG. 15F




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E




FIG. 16F




FIG. 17A




FIG. 17B




FIG. 17C



EUROPEAN SEARCH REPORT

Application Number
EP 21 16 6042

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	AU 2014 201 367 A1 (MERCK SHARP & DOHME) 3 April 2014 (2014-04-03) * the whole document *	1-10	INV. C07K16/28
Y	WO 2008/156712 A1 (MERCK SHARP & DOHME BV) 24 December 2008 (2008-12-24) * abstract *	1-10	
Y	WO 2006/121168 A1 (ONO PHARMACEUTICAL CO [JP]; MEDAREX INC [US]; KORMAN ALAN J; SRINIVASA) 16 November 2006 (2006-11-16) * the whole document *	1-10	
Y	AGATA Y ET AL: "EXPRESSION OF THE PD-1 ANTIGEN ON THE SURFACE OF STIMULATED MOUSE T AND B LYMPHOCYTES", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 8, no. 5, 1 May 1996 (1996-05-01), pages 765-772, XP000971773, ISSN: 0953-8178 * the whole document *	1-10	
Y	WO 2010/036959 A2 (DANA FARBER CANCER INST INC [US]; UNIV EMORY [US] ET AL.) 1 April 2010 (2010-04-01) * the whole document * * in particular, pages 36-41 and 90-92 *	1-10	
Y	US 8 735 553 B1 (LI KANG [CN] ET AL) 27 May 2014 (2014-05-27) * the whole document * * in particular, cols. 16-29, and figures 5-6 *	1-10	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
			A61K C07K
Place of search		Date of completion of the search	Examiner
Munich		18 October 2021	Pérez-Mato, Isabel
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 21 16 6042

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-10-2021

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
AU 2014201367	A1	03-04-2014	NONE

WO 2008156712	A1	24-12-2008	AU 2008266951 A1 24-12-2008
			BR PI0812913 A2 09-12-2014
			BR 122017025062 B1 03-09-2019
			CA 2691357 A1 24-12-2008
			CA 2855098 A1 24-12-2008
			CN 102131828 A 20-07-2011
			CN 104945508 A 30-09-2015
			CY 1114849 T1 22-06-2016
			DK 2170959 T3 13-01-2014
			EP 2170959 A1 07-04-2010
			EP 2535354 A1 19-12-2012
			EP 3222634 A1 27-09-2017
			ES 2437327 T3 10-01-2014
			ES 2616355 T3 12-06-2017
			HK 1140497 A1 15-10-2010
			HR P20131167 T1 03-01-2014
			HU S1500071 I1 29-02-2016
			IL 202813 A 31-03-2015
			JP 5191537 B2 08-05-2013
			JP 5640052 B2 10-12-2014
			JP 2010530753 A 16-09-2010
			JP 2012254092 A 27-12-2012
			KR 20100054780 A 25-05-2010
			KR 20140133954 A 20-11-2014
			KR 20150055114 A 20-05-2015
			LU 92936 I2 29-02-2016
			ME 02093 B 30-04-2014
			NO 2015028 I1 21-12-2015
			NZ 582150 A 31-08-2012
			NZ 600758 A 27-09-2013
			PH 12015501524 A1 22-02-2016
			PL 2170959 T3 31-03-2014
			PT 2170959 E 07-01-2014
			RS 53072 B 30-04-2014
			SI 2170959 T1 30-04-2014
			US 2010266617 A1 21-10-2010
			US 2013108651 A1 02-05-2013
			US 2013109843 A1 02-05-2013
			US 2015232555 A1 20-08-2015
			US 2018111996 A1 26-04-2018
			WO 2008156712 A1 24-12-2008
			ZA 201000135 B 25-05-2011

WO 2006121168	A1	16-11-2006	AU 2006244885 A1 16-11-2006

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 21 16 6042

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-10-2021

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		BR PI0610235 A2	08-06-2010
		CA 2607147 A1	16-11-2006
		CA 2970873 A1	16-11-2006
		CN 101213297 A	02-07-2008
		CN 103059138 A	24-04-2013
		CN 105315373 A	10-02-2016
		CN 109485727 A	19-03-2019
		DK 2161336 T3	28-10-2013
		DK 2439273 T3	03-06-2019
		EP 1896582 A1	12-03-2008
		EP 2161336 A1	10-03-2010
		EP 2418278 A2	15-02-2012
		EP 2439272 A2	11-04-2012
		EP 2439273 A2	11-04-2012
		EP 3530736 A2	28-08-2019
		ES 2427646 T3	31-10-2013
		ES 2720160 T3	18-07-2019
		HK 1140793 A1	22-10-2010
		HU E044719 T2	28-11-2019
		HU S1500067 I1	29-02-2016
		IL 187108 A	30-06-2011
		IL 208642 A	30-08-2012
		JP 4361545 B2	11-11-2009
		JP 5028700 B2	19-09-2012
		JP 5872377 B2	01-03-2016
		JP 6185971 B2	23-08-2017
		JP 2006340714 A	21-12-2006
		JP 2009155338 A	16-07-2009
		JP 2012158605 A	23-08-2012
		JP 2014077015 A	01-05-2014
		JP 2016033135 A	10-03-2016
		JP 2017052784 A	16-03-2017
		JP 2019103504 A	27-06-2019
		KR 20080011428 A	04-02-2008
		KR 20130032908 A	02-04-2013
		KR 20130114226 A	16-10-2013
		LT 2439273 T	10-05-2019
		LU 92904 I2	10-02-2016
		NO 341219 B1	18-09-2017
		NO 344818 B1	04-05-2020
		NO 2018008 I1	14-02-2018
		NZ 563193 A	28-05-2010
		PL 2161336 T3	31-01-2014
		PL 2439273 T3	30-08-2019
		PT 2161336 E	03-10-2013
		PT 2439273 T	13-05-2019

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 21 16 6042

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-10-2021

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		RU 2010135087 A	27-02-2012
		RU 2013133714 A	27-01-2015
		RU 2016133899 A	22-02-2018
		SI 2161336 T1	29-11-2013
		SI 2439273 T1	31-05-2019
		TW 1379898 B	21-12-2012
		US 2009217401 A1	27-08-2009
		US 2013133091 A1	23-05-2013
		US 2014212422 A1	31-07-2014
		US 2014294852 A1	02-10-2014
		US 2014328833 A1	06-11-2014
		US 2014348743 A1	27-11-2014
		US 2015165025 A1	18-06-2015
		US 2017088615 A1	30-03-2017
		US 2020138945 A1	07-05-2020
		WO 2006121168 A1	16-11-2006

WO 2010036959	A2	01-04-2010	AU 2009296392 A1
			AU 2016222431 A1
			AU 2018202800 A1
			AU 2019246763 A1
			BR PI0919377 A2
			CA 2738252 A1
			CA 2998281 A1
			CN 102264762 A
			CN 108484767 A
			DK 2342226 T3
			EP 2342226 A2
			EP 3133086 A1
			EP 3530672 A1
			ES 2592216 T3
			HU E030807 T2
			IL 211830 A
			IL 265397 A
			JP 6087503 B2
			JP 6663653 B2
			JP 6723273 B2
			JP 2012503984 A
			JP 2015214549 A
			JP 2018113969 A
			JP 2020108376 A
			KR 20110079673 A
			KR 20180004288 A
			KR 20180129984 A
			KR 20190107756 A
			MX 349463 B

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 21 16 6042

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-10-2021

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		PL 2342226 T3	31-01-2017
		US 2011271358 A1	03-11-2011
		US 2013291136 A1	31-10-2013
		US 2016137731 A1	19-05-2016
		US 2018371084 A1	27-12-2018
		US 2020172616 A1	04-06-2020
		WO 2010036959 A2	01-04-2010

US 8735553	B1 27-05-2014	AU 2013400609 A1	05-05-2016
		AU 2020201069 A1	05-03-2020
		BR 112016005408 A2	16-01-2018
		CA 2924172 A1	19-03-2015
		CA 3078121 A1	19-03-2015
		CA 3080200 A1	19-03-2015
		CN 105531288 A	27-04-2016
		CN 107011441 A	04-08-2017
		CN 107090041 A	25-08-2017
		CN 108715615 A	30-10-2018
		CN 112457403 A	09-03-2021
		CN 112552401 A	26-03-2021
		DK 3044234 T3	18-05-2020
		EA 201690567 A1	31-08-2016
		EP 3044234 A1	20-07-2016
		EP 3702373 A2	02-09-2020
		ES 2792183 T3	10-11-2020
		HK 1217501 A1	13-01-2017
		HU E049281 T2	28-09-2020
		IL 244514 A	31-03-2020
		IL 272867 A	29-07-2021
		JP 6623353 B2	25-12-2019
		JP 2016533763 A	04-11-2016
		KR 20160044063 A	22-04-2016
		NZ 718643 A	28-02-2020
		PL 3044234 T3	19-10-2020
		PT 3044234 T	27-05-2020
		SG 11201601844T A	28-04-2016
		TW 201538525 A	16-10-2015
		US 8735553 B1	27-05-2014
		US 2015079109 A1	19-03-2015
		US 2015315274 A1	05-11-2015
		US 2018111995 A1	26-04-2018
		US 2018251551 A1	06-09-2018
		US 2020216535 A1	09-07-2020
		US 2021230274 A1	29-07-2021
		WO 2015035606 A1	19-03-2015
		ZA 201601953 B	28-06-2017

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

55

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 21 16 6042

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-10-2021

10

Patent document cited in search report	Publication date	Patent family member(s)	Publication date

15

20

25

30

35

40

45

50

EPO FORM P0459

55

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 62095675 [0001]
- US 62220199 [0001]
- US 62251082 [0001]
- US 62261118 [0001]
- WO 8801649 A [0058]
- US 4946778 A [0058]
- US 5260203 A [0058]
- EP 404097 A [0059]
- WO 9311161 A [0059]
- US 4816567 A [0070]
- US 7022500 B, Queen [0072]
- US 6982321 B, Winter [0072]
- US 6180370 B, Queen [0072]
- US 6054297 A, Carter [0072]
- US 5693762 A, Queen [0072]
- US 5859205 A, Adair [0072]
- US 5693761 A, Queen [0072]
- US 5565332 A, Hoogenboom [0072]
- US 5585089 A, Queen [0072]
- US 5530101 A, Queen [0072]
- US 6072035 A, Hardman [0075]
- US 5639641 A, Pedersen [0075]
- US 6706477 B, Zauderer [0076]
- US 6800442 B, Zauderer [0076]
- US 6872518 B, Zauderer [0076]
- WO 9311794 A [0078]
- US 5766886 A, Studnicka [0078]
- US 5770196 A, Studnicka [0078]
- US 5821123 A, Studnicka [0078]
- US 5869619 A, Studnicka [0078]
- US 4640835 A [0108]
- US 4496689 A [0108]
- US 4301144 A [0108]
- US 4670417 A [0108]
- US 4791192 A [0108]
- US 4179337 A [0108]
- US 4766106 A [0108]
- US 4495285 A [0108]
- US 4609546 A [0108]
- US 6030613 A [0114]
- US 4522811 A [0115]
- US 7776553 B [0138]
- US 8772049 B [0138]

Non-patent literature cited in the description

- NISHIMURA et al. *J. Exp. Med.*, 2000, vol. 101 (5), 891-98 [0005]
- PLUCKTHUN. *The Pharmacology Of Monoclonal Antibodies*. Springer-Verlag, 1994, vol. 113, 269-315 [0058] [0064]
- HOLLIGER et al. *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0059]
- MORRISON et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6851 [0070]
- JONES et al. *Nature*, 1986, vol. 321, 522-525 [0071] [0072]
- RIECHMANN et al. *Nature*, 1988, vol. 332, 323-327 [0071] [0072]
- VERHOEYEN et al. *Science*, 1988, vol. 239, 1534-1536 [0071] [0072]
- WINTER. *FEBS Lett*, 1998, vol. 430, 92-94 [0072]
- SIMS et al. *J. Immunol.*, 1987, vol. 151, 2296 [0073]
- CHOTHIA et al. *J. Mol. Biol.*, 1987, vol. 196, 901 [0073]
- CARTER et al. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 4285 [0073]
- PRESTA et al. *J. Immunol.*, 1993, vol. 151, 2623 [0073]
- VASWAMI et al. *Ann. Allergy & Immunol.*, 1998, vol. 81, 105 [0075]
- ROGUSKA et al. *Prot. Engineer.*, 1996, vol. 9, 895-904 [0075]
- *Antibody Engineering: Methods and Protocols*. Humana Press, 2004, vol. 248 [0079]
- *Current Protocols in Molecular Biology*. John Wiley & Sons, 1992 [0098]
- SAMBROOK et al. *Molecular Cloning: a Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 [0100]
- Goodman and Gilman's *The Pharmacological Basis of Therapeutics*. McGraw-Hill, 2001 [0128]
- *Pharmacotherapeutics for Advanced Practice: A Practical Approach*. Lippincott, Williams & Wilkins, 2001 [0128]
- *Cancer Chemotherapy and Biotherapy*. Lippincott, Williams & Wilkins, 2001 [0128]
- OGUNNYI et al. *Nature Protocols*, 2009 [0139]
- OGUNNYI et al. *Vaccine*, 2014 [0140]
- TILLER et al. *J. Immunol. Methods*, 2009, vol. 350, 183-93 [0141]

EP 3 916 017 A1

- **EWING ; GREEN.** *Genome Research*, 1998, vol. 8, 186-94 [0141]
- **VARADARAJAN et al.** *Proc. Nat'l Acad. Sci.*, 2012, vol. 109, 3885-3890 [0150]